A Multi-site, Phase I/II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of a Prophylactic SARS-CoV-2 RNA Vaccine (BNT162b3) Against COVID-19 Using Different Dosing Regimens in Healthy Adults
Phase: PHASE1
Conditions: Covid-19, Protection Against COVID-19
Sponsor: BioNTech SE

 
 
Page 1 of 133 
 
Statement of Compliance: This trial will be conducted in according to this protocol, the ethical principles that have their 
origin in the Declaration of Helsinki, good clinical practice (GCP), and applicable regulatory requirements. 
Confidentiality Statement: The information contained in this document is the property and copyright of BioNTech SE. 
Therefore, this document is provided in confidence to the recipient. No information contained herein shall be published, 
disclosed or reproduced without prior written approval of the proprietor(s). 
 
CLINICAL TRIAL PROTOCOL INCLUDING  
AMENDMENTS NOS. 01 TO 04 
BNT162-04 
 
Version: 
10.0 
Date: 
12 MAY 2021 
Sponsor: 
BioNTech SE 
 
 
 
Trial title: 
A multi-site, Phase I/II, 2-part, dose escalation trial investigating the safety and 
immunogenicity of a prophylactic SARS-CoV-2 RNA vaccine (BNT162b3) 
against COVID-19 using different dosing regimens in healthy adults 
Brief title: 
A multi-site Phase I/II trial investigating the safety and effects of one BNT162 
vaccine against COVID-19 in healthy adults 
Trial phase: 
Phase I/II 
Indication: 
Protection against COVID-19 
Product: 
BNT162b3, SARS-CoV-2 - RNA lipid nanoparticle (RNA-LNP) vaccine utilizing 
the nucleoside modified messenger RNA (modRNA) format 
Coordinating and 
Principal investigator:  
Dr. Dr. med. Armin Schultz, CRS Clinical Research Services Mannheim 
GmbH, Germany (tel.: +49 621 15045 
) 
Contract research 
organization (CRO): 
CRS Clinical Research Services Mannheim GmbH, Germany 
Trial sites: 
CRO sites in one or more of Berlin, Kiel, and Mannheim (Germany) 
Sponsor’s medical 
representative: 
Elizabeth Adams, MD, Senior Medical Director, BioNTech US, Inc. 
Sponsor: 
BioNTech SE, An der Goldgrube 12, 55131 Mainz, Germany 
Regulatory identifiers: 
EudraCT no.: 2020-003267-26; Universal Trial Number: U1111-1254-4840; 
Clinicaltrials.gov code: NCT04537949 
Medical Monitor: 
The name and contact information will be provided separately 
 
Document history 
Date 
Version No. 
Valid for  
Approved version* 
03 JUL 2020 
1.0 
Germany 
Approved version* 
06 JUL 2020 
2.0 
Germany 
Approved version* (implementing Paul-Ehrlich-Institut (PEI) feedback 
on version 2.0) 
16 AUG 2020 
3.0 
Germany 
Approved version* (implementing Independent Ethics Committee 
(IEC) feedback on version 2.0 in version 3.0) 
16 AUG 2020 
4.0 
Germany 
Approved version* (implementing amendment 01) 
15 SEP 2020 
5.0 
Germany 
Approved version* (implementing PEI feedback on amendment 01) 
06 OCT 2020 
6.0 
Germany 
Approved version* (implementing IEC feedback on amendment 01) 
28 OCT 2020 
7.0 
Germany 
Approved version* (implementing amendment 02) 
02 DEC 2020 
8.0 
Germany 
Approved version* (implementing amendment 03) 
25 MAR 2021 
9.0 
Germany 
Approved version* (implementing amendment 04) 
12 MAY 2021 
10.0 
Germany 
* Denotes BioNTech approved versions. 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 4 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
In Cohort 1, the sentinel dosing/subject staggering process will be as follows: 
 One sentinel subject will be dosed on one day. 
 If the dosing in this subject was considered to be safe and well tolerated by the 
investigator after 24±2 h observation on site, a 5 further subjects will be dosed (with 
intervals of at least 1 h between subjects). 
 If the dosing in these 5 subjects was considered to be safe and well tolerated by the 
investigator based on 48 h data (24±2 h observation on site and phone interview for 
assessment 48±2 h after immunization; in addition to the available 48±2 h data from 
the sentinel subject): 
− 
The remaining 6 subjects in the group will be dosed (with intervals of at least 
30 min between subjects). 
− 
If approved by the SRC, the next planned escalation dose (see Table 1) in 
Cohort 2 may be initiated. The data assessed by the SRC comprises 48 h data 
for 6 subjects including observation on site, phone interview, vital signs, 
TEAEs, local reactions, blood/clinical laboratory data, and brief physical 
examination outcome. 
− 
Once dose escalation is approved, the planned dose de-escalations may also 
be initiated. 
For any subsequent dose escalation cohorts, the sentinel/subject staggering process will 
be as follows: 
 Two sentinel subjects will be dosed on one day (with intervals of at least 30 min 
between subjects). 
 If the dosing in these subjects was considered to be safe and well tolerated by the 
investigator after 24±2 h observation on site, a 4 further subjects will be dosed (with 
intervals of at least 30 min between subjects). 
 If the dosing in these 4 subjects was considered to be safe and well tolerated by the 
investigator based 48 h data (24±2 h observation on site and phone interview for 
assessment 48±2 h after immunization; in addition to the available 48 h data from 
the sentinel subjects): 
− 
The remaining 6 subjects in the group will be dosed (with intervals of at least 
30 min between subjects). 
− 
If approved by the SRC, the next planned escalation dose (see Table 1) may 
be initiated. The data assessed by the SRC comprises 48 h data for 6 subjects 
(including observation on site, short summary of phone interviews [including 
statement about diary reports], vital signs, investigator reported local and 
systemic reactions, TEAEs, solicited local & systemic reactions, blood/clinical 
laboratory data, and brief physical examination outcome). 
The maximum allowed dose for each vaccine candidate is defined in the Table 1. 
For any dose de-escalation or dose-refinement cohorts in younger adults, i.e., cohorts with 
doses lower than previously tested, 12 subjects will be dosed using a subject staggering 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 5 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
(6-6) process (with intervals of at least 30 min between subjects). The doses in these 
cohorts must be lower than doses that have shown acceptable tolerability in younger 
adults (based on the data from 12 subjects up until 48 h after the first dose). The same 
dose will not be administered twice, i.e., in two cohorts. 
 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 7 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
For an overview of BNT162b vaccines in ongoing clinical trials, see the current BNT162 IB. See below for a summary and Section 2.1.3 for details. 
BNT162b1: 
 BNT162b1 P/B doses of 1, 10, 30, and 50 µg showed acceptable tolerability in younger adults. 
 Based on the tolerability profile after the prime dose at 60 µg (BNT162-01 trial) and 100 µg (BNT162-02 trial), the respective boost doses were not administered. 
 BNT162b1 P/B doses of 10, 20, and 30 µg showed acceptable tolerability in elderly adults. This tolerability appears to be better than seen in younger adults at the same doses. 
BNT162b2: 
 BNT162b2 P/B doses of 1, 10, and 30 µg showed acceptable tolerability in younger adults. 
 BNT162b2 P/B doses of 10, 20, and 30 µg in elderly adults. This tolerability appears to be better than seen in younger adults at the same doses. 
 
Based on the BNT162b1 and BNT162b2 tolerability data summarized above, and the implemented safety measures (sentinel/staggered subject dosing, post-dose observation 
period, wellbeing questioning, etc.) as described in the section Risk assessment, the planned BNT162b3 doses in older adults in this trial are expected to show acceptable 
tolerability. 
Based on the available immunogenicity and cell-mediated immune response data after dosing with BNT162b1 and BNT162b2 in younger and elderly adults in the BNT162-01 and 
BNT162-02 trials (see the BNT162 IB), the BNT162b3 doses planned in this trial in older adults are also expected to show measurable responses. These vaccines elicited 
measurable but lower responses in elderly adults than in younger adults, therefore, this trial includes the option to investigate BNT162b3 doses above the 30 µg 
BNT162b1/BNT162b2 doses already tested in elderly adults, to support any future Phase III program planned to support marketing approval. 
Altogether, the doses planned in older adults in this trial are considered adequate to support the trial objectives and to pose an acceptable risk to trial subjects. 
 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 9 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
Trial duration 
In total, the planned trial duration is expected to be approximately 16 months. From 
screening visit (Visit 0) to the last visit (Visit 10), each trial subject will be in the trial for 
maximally 417 days (i.e., from Day -30 to Day 387). 
Population 
Healthy adults aged 18 to 55 years (Cohorts 1 to 7; younger adults) or aged 56 to 85 years 
(Cohorts 8 to 10; older adults). Subjects aged 56 to 85 years must be enrolled such that at 
least 6 subjects per cohort are aged 65 to 85 years (i.e., are elderly). 
Twelve subjects are required for each of the cohorts planned in Part A. Assuming all 
cohorts planned in Table 1 are performed, 144 subjects will be required. 
Key inclusion criteria 
Volunteers are only eligible to be enrolled in the trial if they meet the following criteria: 
 For younger adult cohorts, volunteers must be aged 18 to 55 years, have a body 
mass index (BMI) over 19 kg/m2 and under 30 kg/m2 (i.e., be neither underweight 
nor obese), and weigh at least 50 kg at Visit 0. 
OR 
For older adult cohorts, volunteers must be aged 56 to 85 years, have a BMI over 
19 kg/m2 and under 30 kg/m2 (i.e., be neither underweight nor obese), and weigh at 
least 50 kg at Visit 0. 
 They must be healthy, in the clinical judgment of the investigator, based on medical 
history, physical examination, 12-lead electrocardiogram (ECG), vital signs 
(systolic/diastolic blood pressure, pulse rate, body temperature, respiratory rate), 
and clinical laboratory tests (blood chemistry, hematology, and urine chemistry) at 
Visit 0. 
Note: Healthy volunteers with pre-existing stable disease, defined as disease not 
requiring significant change in therapy or hospitalization for worsening disease 
during the 6 wks before enrollment, can be included. 
 Women of childbearing potential (WOCBP) must have a negative beta-human 
chorionic gonadotropin urine test at Visit 0 and Visit 1. Women that are post-
menopausal or permanently sterilized will be considered as not having reproductive 
potential. 
Key exclusion criteria 
Volunteers are excluded from the trial if they present any of the following criteria: 
 Have had any acute illness, as determined by the investigator, with or without fever, 
within 72 h prior to any immunization. An acute illness which is nearly resolved with 
only minor residual symptoms remaining is allowable if, in the opinion of the 
investigator, the residual symptoms will not compromise their wellbeing if they 
participate as trial subjects in the trial, or that could prevent, limit, or confound the 
protocol-specified assessments. 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 10 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
 Have a known allergy, hypersensitivity, or intolerance to the planned IMP including 
any excipients of the IMP. 
 Had any medical condition or any major surgery (e.g., requiring general anesthesia) 
within the past 5 years which, in the opinion of the investigator, could compromise 
their wellbeing if they participate as trial subjects in the trial, or that could prevent, 
limit, or confound the protocol-specified assessments. 
 Have any surgery planned during the trial, starting after Visit 0 and continuously 
until at least 90 d after receiving the last immunization. 
 Had any chronic use (more than 21 continuous days) of any systemic medications, 
including immunosuppressants or other immune-modifying drugs, within the 
6 months prior to Visit 0 unless in the opinion of the investigator the medication 
would not prevent, limit, or confound the protocol-specified assessments or could 
compromise subject safety. 
 Note: Healthy participants with pre-existing stable disease, defined as disease not 
requiring significant change in therapy or hospitalization for worsening disease 
during the 6 wks before enrollment, can be included. 
 Regular receipt of inhaled/nebulized corticosteroids. 
 Had any vaccination within the 28 d prior to Visit 0. 
 Had administration of any immunoglobulins and/or any blood products within the 
3 months prior to Visit 0. 
 Had administration of another IMP including vaccines within 60 d or 5 half-lives 
(whichever is longer), prior to Visit 0. 
 Have a known history or a positive test of any of human immunodeficiency virus 
(HIV) 1 or 2, Hepatitis B, or Hepatitis C, within the 30 d prior to Visit 0. 
 Have a positive PCR-based test for SARS-CoV-2 within the 30 d prior to Visit 1. 
 Previously participated in an investigational trial involving lipid nanoparticles. 
 Have a history (within the past 5 years) of substance abuse or known medical, 
psychological, or social conditions which, in the opinion of the investigator, could 
compromise their wellbeing if they participate as trial subjects in the trial, or that 
could prevent, limit, or confound the protocol-specified assessments. 
 Have a history of hypersensitivity or serious reactions to previous vaccinations. 
 Have a history of Guillain-Barré Syndrome within 6 wks following a previous 
vaccination. 
 Have a history of narcolepsy. 
 Have a history of or suspected immunosuppressive condition, acquired or 
congenital, as determined by medical history and/or physical examination at Visit 0. 
 Have symptoms of the Coronavirus Disease 2019 (COVID-19), e.g., respiratory 
symptoms, fever, cough, shortness of breath and breathing difficulties. 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 11 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
 Have had contact with persons diagnosed with COVID-19 or who tested positive for 
SARS-CoV-2 by any diagnostic test within the 30 d prior to Visit 1. 
 Are soldiers, persons in detention, CRO or sponsor staff or their family members. 
 Have a condition known to put them at high risk for severe COVID-19, including 
those with any of the following risk factors: 
o Cancer 
o COPD (chronic obstructive pulmonary disease) 
o Immunocompromised state (weakened immune system) from solid organ 
transplant 
o Obesity (BMI of 30 or higher) 
o Serious heart conditions, such as heart failure, coronary artery disease, or 
cardiomyopathies 
o Sickle cell disease 
o Diabetes mellitus 
o Hypertension 
o Asthma 
o Chronic liver disease 
o Known Stage 3 or worse chronic kidney disease (glomerular filtration rate 
<60 mL/min/1.73 m2) 
o Anticipating the need for immunosuppressive treatment within the next 6 months 
o Resident in a long-term facility 
o Current vaping or smoking (occasional smoking is acceptable) 
o History of chronic smoking within the prior year 
 
Trial treatments (BNT162 vaccine) 
Name: 
BNT162 vaccine - Anti-viral RNA vaccine for active immunization against COVID-19. 
Type: 
RNA-LNP vaccine utilizing the BioNTech modRNA format: product code BNT162b3. 
Dosage levels: 
See Table 1. The planned dose per vaccine candidate will not exceed the pre-defined 
maximum dose (see Table 1).  
Dosage 
frequency: 
Two injections 21 d apart. Injection volumes will be up to 1.5 mL. 
Administration 
route: 
Intramuscular (IM); upper arm, musculus deltoideus. The same arm may be used for 
both immunizations. The non-dominant arm is preferred. 
Statistics 
The final analysis will be performed once all subjects have completed the End of 
Treatment (EoT Visit; Visit 7). An analysis update will be performed once all subjects will 
have completed Visit 10. No formal interim statistical analysis will be performed. However, 
the preliminary analyses may be performed for each cohort once subjects within a cohort 
will have been followed up for at least 7 d following the dose. 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 12 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
Committees 
A Safety Review Committee is planned. 
1.2 
Schema (graphical representation of the trial) 
For a graphical depiction of the dose-ranging process in Part A, see Figure 1. 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 13 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
Dose cohort schema for BNT162b3 (P/B) c 
Cohorts with younger adults 
 
The above schema depicts one sequence of cohorts. Cohorts 5 to 7 include doses lower than Cohort 4 (which uses the maximum 
planned dose in this trial), and thus the sponsor may decide to perform one or more of Cohorts 5 to 7 before proceeding to Cohort 4. 
Cohorts with older adults d 
 
a) The data assessed by the SRC for progressing comprises 48 h data for 6 subjects. 
b) Cohorts 5 to 7 are planned for dose-refinement. If they use doses lower than already tested, a staggered (6-6) 
subject dosing process will be used and the cohorts may be conducted in parallel to each other and to any dose 
escalation cohorts. If they use doses higher than already tested, subjects will be dosed using a sentinel 
dosing/subject (2-4-6) staggering process. 
c) For the dose regimens, see Table 1 and Table 2. 
d) Cohorts 8 to 12 are planned in older adults. For Cohort 8 and any dose escalation cohorts in older adults, 12 subjects 
will be dosed using a sentinel dosing/subject staggering (2-4-6) process. 
 
Figure 1: 
Graphical depiction of the dose-finding process in Part A 
FIH = First in humans; h = hour(s); SRC = Safety Review Committee. 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 17 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
i) 
Only for the first 6 subjects per group. Questioning on and documentation of adverse events (AEs) as well as systemic and local reactions, the latter in case of upcoming 
dose decision meetings. 
j) 
Only IMP-related AEs and any SAEs except proven COVID-19 cases which have to be reported regardless on severity and relatedness to the trial drug until the last 
scheduled FU Visit as described into the Section 10.3.1.9. 
k) 
Blood draw for anti-SARS-CoV-2 antibodies. 
l) 
For Cohorts 1 and 8, prime immunization with at least 1 h intervals between subjects for the first 6 subjects and then with at least 30 min intervals for the remaining 
6 subjects. For all other cohorts, immunization with at least 30 min intervals between subjects. Boost immunization with at least 15 min intervals between subjects. 
m) Oral swipe for SARS-CoV-2 testing either on Day -1 or at the Visit 1 on Day 1. 
n) 
The listed blood draw days may be adapted if justified by the collected data. Leftover blood after completion of the immunogenicity assessments may be used for additional 
analyses as described in Section 8.7 (Genetics) and/or Section 8.8 (Biomarkers). 
o) 
For subjects who have given consent, one aliquot of the blood sample drawn for analysis of CMI may be used for HLA typing to allow additional analysis of T-cell receptor 
repertoire and/or phenotypic characterization of T cells specific to vaccine encoded antigens. 
p) 
If HLA typing using the blood sample collected with Lithium Heparin is not conclusive, EDTA-blood will be drawn for HLA testing. 
q) 
Record any medications that trial subjects receive during the trial in the CRF starting after Visit 0 and until the respective EoT Visit; record any vaccination, including 
SARS-CoV-2 vaccination that subjects receive, after the EoT Visit until the last FU Visit in the CRF. 
 
Note: If the boost dose is not administered, subjects should still complete all assessments planned in the SoA. 
 
Abbreviations: AE = adverse event; CMI = cell-mediated immune testing; CRF = case report form; D or d = day; ECG = electrocardiogram; EDTA = ethylenediamine tetraacetic acid; 
EoT = End of Treatment (Visit); FU = follow-up (visit); h = hour(s); HLA = human leukocyte antigen; min = minute(s); Day 0 = one day before Day 1; IMP = investigational medicinal 
product; min = minute(s); SARS-CoV-2 = the virus leading to COVID-19; WOCBP = women of childbearing potential. 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 18 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
TABLE OF CONTENTS 
1 
PROTOCOL SUMMARY 
2 
1.1 
Trial synopsis 
2 
1.2 
Schema (graphical representation of the trial) 
12 
1.3 
Schedule of activities 
14 
TABLE OF CONTENTS 
18 
LIST OF TABLES 
22 
LIST OF FIGURES 
22 
TRIAL-SPECIFIC ABBREVIATIONS/TERMS 
23 
2 
INTRODUCTION 
24 
2.1 
Background 
24 
2.1.1 
Overview of the disease 
24 
2.1.2 
Introduction to BioNTech RNA-based vaccines 
24 
2.1.3 
Ongoing and planned clinical trials with BNT162 vaccine variants 
25 
2.2 
Trial rationale 
25 
2.3 
Benefit/risk assessment 
26 
2.3.1 
Risk assessment 
26 
2.3.2 
Benefit assessment 
30 
2.3.3 
Overall benefit/risk conclusion 
30 
3 
OBJECTIVES AND ENDPOINTS 
31 
4 
TRIAL DESIGN 
32 
4.1 
Overall design 
32 
4.1.1 
Adaptive trial design elements 
34 
4.1.2 
Planned number of trial subjects 
34 
4.2 
Scientific rationale for the trial design 
35 
4.3 
Justification for dose 
35 
4.4 
End of Treatment (EoT) and end of trial definition 
37 
5 
TRIAL POPULATION 
38 
5.1 
Inclusion criteria 
38 
5.1.1 
Inclusion criteria Part A 
38 
5.2 
Exclusion criteria 
39 
5.2.1 
Exclusion criteria Part A 
39 
5.3 
Lifestyle considerations 
41 
5.4 
Screen failures 
41 
6 
TRIAL TREATMENTS 
42 
6.1 
IMP administered 
42 
6.2 
Preparation/handling/storage/accountability 
42 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 19 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
6.3 
Measures to minimize bias: randomization and blinding 
42 
6.4 
Trial treatment compliance 
42 
6.5 
Concomitant therapy 
43 
6.5.1 
Premedication 
43 
6.5.2 
Rescue medication 
43 
6.6 
Dose modifications 
43 
6.6.1 
Dose limiting toxicity 
44 
6.6.2 
Dose modification guidance/rules 
45 
6.6.3 
Mitigation plans for specific AEs 
45 
6.6.4 
Safety stopping criteria 
46 
6.7 
Treatment after the end of the trial 
46 
7 
DISCONTINUATION OF TRIAL TREATMENT AND TRIAL SUBJECT 
DISCONTINUATION/WITHDRAWAL 
47 
7.1 
Discontinuation of trial treatment 
47 
7.1.1 
Temporary discontinuation 
47 
7.1.2 
Rechallenge 
47 
7.2 
Trial subject discontinuation/withdrawal from the trial 
47 
7.3 
Lost to follow-up 
48 
7.4 
Replacement of permanently discontinued trial subjects 
48 
8 
TRIAL ASSESSMENTS AND PROCEDURES 
49 
8.1 
Efficacy assessments 
49 
8.2 
Safety assessments 
49 
8.2.1 
Physical examinations 
49 
8.2.2 
Vital signs 
49 
8.2.3 
Electrocardiograms 
50 
8.2.4 
Clinical laboratory tests 
50 
8.2.5 
Drugs of abuse screening 
50 
8.2.6 
Testing for alcohol use 
50 
8.2.7 
Viral screening (for blood-borne viruses) 
51 
8.2.8 
Subject diaries 
51 
8.2.9 
Assessment of local reactions 
51 
8.2.10 
SARS-CoV-2 testing 
51 
8.2.11 
Subject hotline 
52 
8.2.12 
Subject wellbeing questioning 
52 
8.2.13 
Assessment of systemic reactions 
52 
8.3 
Adverse events and serious adverse events 
53 
8.3.1 
Time period and frequency for collecting AE and SAE information 
53 
8.3.2 
Method of detecting AEs and SAEs 
53 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 20 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
8.3.3 
Follow-up of AEs and SAEs 
53 
8.3.4 
Regulatory reporting requirements for SAEs 
54 
8.3.5 
Pregnancy 
54 
8.3.6 
Death events 
55 
8.3.7 
Disease-related events and/or disease-related outcomes not qualifying as AEs 
or SAEs 
55 
8.3.8 
Adverse events of special interest 
55 
8.4 
Treatment of overdose 
55 
8.5 
Pharmacokinetics 
55 
8.6 
Pharmacodynamics 
55 
8.7 
Genetics 
56 
8.8 
Biomarkers 
56 
8.9 
Immunogenicity assessments 
57 
8.10 
Blood collection 
57 
9 
STATISTICAL CONSIDERATIONS 
58 
9.1 
Statistical hypotheses 
58 
9.2 
Sample size determination 
58 
9.3 
Analysis sets 
58 
9.4 
Statistical analyses 
58 
9.4.1 
General considerations 
58 
9.4.2 
Primary endpoints 
59 
9.4.3 
Secondary endpoints 
60 
9.4.4 
Exploratory endpoints 
60 
9.4.5 
Other safety analyses 
60 
9.4.6 
Other analyses 
61 
9.5 
Interim analyses 
61 
9.6 
Data monitoring committee 
61 
10 
SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS 
62 
10.1 
Regulatory, ethical, and trial oversight considerations 
62 
10.1.1 
Regulatory and ethical considerations 
62 
10.1.2 
Financial disclosure 
63 
10.1.3 
Informed consent process 
63 
10.1.4 
Data protection 
63 
10.1.5 
Committees - SRC 
64 
10.1.6 
Dissemination of clinical trial data 
64 
10.1.7 
Data quality assurance 
64 
10.1.8 
Source documents 
65 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 21 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
10.1.9 
Trial and site start and closure 
65 
10.1.10 
Publication policy 
66 
10.1.11 
Protocol preparation and approval 
66 
10.2 
Clinical laboratory tests 
66 
10.3 
Adverse events: Definitions and procedures for recording, evaluating, follow-up, 
and reporting 
67 
10.3.1 
Definition of AE and TEAE 
67 
10.4 
Contraceptive guidance and collection of pregnancy information 
78 
10.4.1 
Definitions 
78 
10.4.2 
Contraception guidance 
79 
10.4.3 
Collection of pregnancy information 
80 
10.4.4 
Sperm donation 
80 
10.5 
Genetics 
80 
10.6 
Liver safety: Suggested actions and follow-up assessments 
81 
10.7 
Investigators and trial administrative structure 
81 
10.7.1 
Investigators and trial site personnel 
81 
10.7.2 
Trial site personnel assigned trial-related duties 
81 
10.7.3 
Contract research organizations 
81 
10.7.4 
The sponsor and sponsor’s personnel 
81 
10.8 
Country-specific requirements 
82 
10.9 
Other standard abbreviations and definitions 
82 
10.10 
Protocol amendments and updates 
83 
10.10.1 
Update to protocol version 2.0 
83 
10.10.2 
Update to protocol version 3.0 
83 
10.10.3 
Update to protocol version 4.0 
85 
10.10.4 
Protocol amendment no. 01 (protocol version 5.0) 
91 
10.10.5 
Protocol amendment no. 01 (protocol version 6.0) 
103 
10.10.6 
Protocol amendment no. 01 (protocol version 7.0) 
106 
10.10.7 
Protocol amendment no. 02 (protocol version 8.0) 
109 
10.10.8 
Protocol amendment no. 03 (protocol version 9.0) 
115 
10.10.9 
Protocol amendment no. 04 (protocol version 10.0) 
127 
10.11 
Data collection and management 
130 
10.11.1 
Case report forms 
130 
10.11.2 
Trial subject reported outcomes 
130 
10.11.3 
Data management 
130 
10.11.4 
Investigator’s Site File and the Trial Master File 
130 
10.12 
Other data 
131 
10.12.1 
Demographic data 
131 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 22 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
10.12.2 
Medical history 
131 
11 
REFERENCES 
132 
 
LIST OF TABLES 
Table 1: 
Summary of vaccine dose regimens for younger adults aged 18 to 55 years in 
Part A 
6 
Table 2: 
Summary of vaccine dose regimens for older adults aged 56 to 85 years in 
Part A 
6 
Table 3: 
Schedule of trial procedures and assessments – BNT162b3 
14 
Table 4: 
Local reaction grading scale 
76 
Table 5: 
Systemic reaction grading scale 
76 
Table 6: 
Fever grading scale 
77 
Table 7: 
Laboratory abnormality grading scale 
77 
 
LIST OF FIGURES 
Figure 1: Graphical depiction of the dose-finding process in Part A 
13 
 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 24 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
2 
INTRODUCTION 
2.1 
Background 
2.1.1 Overview of the disease 
Severe Acute Respiratory Syndrome (SARS) -CoV-2 infections and the caused disease 
Coronavirus Disease 2019 (COVID-19) are increasing every day and spreading globally, 
affecting more and more countries. 
On March 11th, 2020 the World Health Organization (WHO) characterized the COVID-19 
outbreak as a pandemic. 
The WHO Situation Update Report dated June 30th, 2020 noted 9,843,073 confirmed 
cases with 495,760 deaths globally and 2,656,437 confirmed cases with 196,541 deaths in 
Europe (WHO Situation Report Nr. 160).There are at least three SARS-CoV-2 vaccines for 
preventing COVID-19 disease that have received either Conditional Marketing 
Authorization in Europe or Emergency Use Authorization in the United States. 
2.1.2 Introduction to BioNTech RNA-based vaccines 
An LNP-formulated RNA-based vaccine would provide one of the most flexible, scalable 
and fastest approaches to provide protection against the emerging viruses like 
SARS-CoV-2 (Rauch et al. 2018; Sahin et al. 2014). 
The development of an RNA-based vaccine encoding a viral antigen that is translated to 
protein by the vaccinated organism to induce a protective immune response provides 
significant advantages over more conventional vaccine approaches. Unlike live attenuated 
vaccines, RNA vaccines do not carry the risks associated with infection and may be given 
to people who cannot be administered live virus (such as pregnant women and 
immunocompromised persons). RNA-based vaccines are manufactured via a cell-free 
in vitro transcription process, which allows an easy and rapid production, and the prospect 
of producing high numbers of vaccination doses within a shorter time period than achieved 
with conventional vaccine approaches. This capability is pivotal to enable the most 
effective response in outbreak scenarios. 
The development of in vitro transcribed RNA as an active platform for the use in infectious 
disease vaccines is based on the extensive knowledge of the company in RNA 
technology, which has been gained over the last decade. The core innovation is based on 
in vivo delivery of a pharmacologically optimized, antigen-encoding RNA to induce robust 
neutralizing antibodies and a concomitant T-cell response to achieve protective 
immunization with minimal vaccine doses (Vogel et al. 2018; Moyo et al. 2018; 
Pardi et al. 2017). 
At BioNTech, there are three different RNA platforms under development, namely non-
modified uridine containing mRNA (uRNA, BNT162a), nucleoside modified mRNA 
(modRNA, BNT162b), and self-amplifying mRNA (saRNA, BNT162c). 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 25 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
All three RNA platforms have been tested in more than a dozen non-clinical GLP safety 
studies and there is pre-existing clinical safety data available (see the 
BNT162 investigator’s brochure [IB] and Section 2.1.3). 
The non-clinical toxicity data generated by BioNTech suggest a favorable safety profile for 
uRNA and modRNA, as well as saRNA formulated with different nanoparticles for various 
administration routes, including intravenous (IV) injection. The favorable safety profile after 
IV dosing is notable because it results in a higher systemic exposure than the planned IM 
dosing in this trial. Overall, the findings were mild and mostly related to the mode-of-action 
and the RNA-intrinsic stimulation of innate immune sensors. No unsuspected target 
organs of toxicity were identified. The non-clinical safety profile of uRNA and modRNA in 
rodents was predictive for clinical safety. For further details, see the BNT162 IB. 
The safety and toxicity of the lipid nanoparticle enveloped uRNA, modRNA, and saRNA 
vaccines encoding coronavirus antigens is currently being analyzed in a GLP-compliant 
repeated-dose toxicity study. 
A summary of the available clinical data for the three RNA platforms is given in 
Section 2.1.3. 
2.1.3 Ongoing and planned clinical trials with BNT162 vaccine variants 
Multiple SARS-CoV-2 RNA vaccine platforms (BNT162) have undergone evaluation since 
the advent of the SARS-CoV-2 pandemic. BNT162b3, like BNT162b2, the SARS-CoV-2 
vaccine (Comirnaty) that received Conditional Marketing Authorization at the end of 2020, 
is a modRNA. RNA modifications are known to impact the extent of innate immune 
activation at a given dose level, and thus potentially the extent of reactogenicity 
(Weissman and Karikó 2015). Therefore, tolerability data obtained with the BNT162b1 and 
BNT162b2 vaccine variants was evaluated in the context of the data on BNT162b3 and 
taken into consideration by the SRC for recommendations of lower or interim doses. 
BNT162 vaccine candidates based on the uRNA, modRNA, and saRNA formats are 
currently under investigation in clinical trials. 
For the design, status, number of trial subjects dosed at least once with a BNT162 vaccine 
candidate, and summary of the available results of the ongoing clinical trials, see the 
current BNT162 IB. 
2.2 
Trial rationale 
SARS-CoV-2 infections and the caused disease COVID-19 are increasing every day and 
spreading globally, affecting more and more countries (for more details, see 
Section 2.1.1). 
BioNTech has developed a technology platform of RNA-based vaccines which enables the 
rapid development of vaccines against emerging viral diseases (for more details, see 
Section 2.1.2). This technology platform is especially attractive because it has the ability to 
deliver high numbers of vaccine doses rapidly in a single production campaign. 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 26 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
This trial will investigate the potential safety and immunogenicity of a prophylactic BNT162 
vaccine against SARS-CoV-2, the candidate BNT162b3. 
2.3 
Benefit/risk assessment 
More detailed information about the known and expected benefits and risks and 
reasonably expected TEAEs for this trial are given in the BNT162 IB. 
2.3.1 Risk assessment 
The risks linked to the trial-specific procedures and connected mitigations are as follows: 
 The volume of blood drawn will be kept to a minimum and will remain less than that 
drawn when donating blood (up to approximately 602 mL blood will be drawn per 
subject over the complete trial, i.e., over approximately 16 months). 
 All trial-specific procedures will be performed by qualified trial site personnel. 
 Immunization will be done by a physician. 
 BNT162b3 has not been administered to humans prior to this trial. However, clinical 
data is available for RNAs formulated with related but not identical liposomal 
compositions or non-formulated RNAs and can support risk assessment of the 
BNT162 vaccines. Also, BNT162b3, like the BNT162b variants BNT162b1 and 
BNT162b2 that are under investigation in the trials BNT162-01, BNT162-02, and 
BNT162-03, are modRNAs. RNA modification is known to impact the extent of 
innate immune activation at a given dose level, and thus potentially the extent of 
reactogenicity (Weissman and Karikó 2015). Therefore, tolerability data obtained 
with the BNT162b1 and BNT162b2 vaccine variants may be potentially informative 
for BNT162b3. 
Based on such data, the risks linked to the immunization with the BNT162b vaccines are 
as follows: 
 Due to the IM route of administration, there is the risk of local reactions at the 
injection site, e.g., erythema, pruritus, pain, tenderness, swelling, sweating. 
 Due to their immune-modulatory effect, vaccines may cause systemic flu-like 
reactions such as temporary headache, fatigue, loss of appetite, myalgia, arthralgia, 
fever. Rarely, with certain prophylactic vaccines (e.g., as seen for vaccines using 
attenuated viruses) severe allergic reactions or a neurological side effect, such as a 
seizure, were seen. Although these rare side effects are a concern, the risk of a 
vaccine causing serious harm or death is considered to be extremely small, in 
particular for BNT162 vaccines, which are molecularly defined, highly purified and 
based on RNA, which naturally occurs and is metabolized in the human organism. 
 Due to the IM route the risk of severe systemic reactions is considered low. 
 An IM vaccine based on modRNA encapsulated into a related but not identical 
vaccination has reported mostly mild to moderate, mostly local solicited AEs (mostly 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 27 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
injection site pain) of 1-3 d duration that resolved without intervention. Fever was 
the only systemic solicited AE (Feldman et al. 2019). 
 As with other vaccines, and with single stranded RNA being an innate immune 
sensor-agonist, BNT162 vaccine administration may cause temporary headache, 
fatigue, or loss of appetite. Rarely, with certain prophylactic vaccines (e.g., as seen 
for vaccines using attenuated viruses) severe allergic reactions or a neurological 
side effect, such as seizures, were seen. Although these rare side effects are a 
concern, the risk of a vaccine causing serious harm or death is considered to be 
extremely small, in particular for BNT162 vaccines, which are molecularly defined, 
highly purified, subunit vaccines. 
The available non-clinical data of BNT162b suggest a favorable safety profile with events 
that are short-lived, mild, and mostly related to the mode-of-action and the RNA-intrinsic 
stimulation of innate immune sensors. 
 Based on the available clinical and non-clinical data on the individual components 
(RNA, the specific LNP formulation), that are combined within the BNT162b 
products, a favorable safety profile of BNT162 products is expected with mild and 
localized effects (see the BNT162 IB for details on these trials). 
To date most of the AEs reported after immunization with BNT162 vaccine candidates, 
including BNT162b vaccine candidates (BNT162b1, BNT162b2, and BNT162b3), were 
mild to moderate in intensity. 
 Generally, good tolerability was observed. Overall, many of the reported AEs 
appear to be similar to reactogenicity events anticipated for intramuscularly (IM)-
administered vaccines, typically with an onset within first 24 h post-immunization. All 
AEs / reactogenicity symptoms resolved spontaneously, mostly within 24 h of onset, 
and were managed with simple measures (e.g., paracetamol). There were no 
serious adverse events (SAEs) and no unexpected toxicities. Fever of severe 
intensity has been reported. Most AEs were managed with simple measures and 
resolved spontaneously. Please refer to the current BNT162 IB. 
 While the general risk of effects potentially associated with the innate immune 
activation and transient secretion of associated cytokines are defined above based 
on the described data, the dose response-relationship, and thus the tolerability for 
BNT162b3 will be defined in this trial and supported by data for other BNT162 
vaccine candidates, including BNT162b vaccine candidates, from the ongoing trials 
(BNT162-01 and BNT162-02). 
 When assessing the risk for dosing of older subjects with BNT162b3 in this trial, the 
follow information is relevant: 
− 
Preliminary data in younger and elderly adults treated in the ongoing BNT162 
trials, backed by non-human primate (rhesus macaque) immunogenicity data, 
BNT162b1, and non-human primate data for BNT162b3, show immunogenicity 
in the tested dose ranges. 
− 
After administration of the prime dose of BNT162b1 and BNT162b2 in (each) 
36 healthy elderly adults in the trial BNT162-02, the local tolerability of 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 28 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
BNT162b1 in elderly adults seemed comparable to that recorded in younger 
adults. The pattern of systemic reactogenicity appeared similar between the 
two age groups, possibly with a lower overall incidence in the elderly adults in 
comparison to the younger adults at equal doses. 
− 
Based on the available immunogenicity and cell-mediated immune response 
data after dosing with BNT162b1 and BNT162b2 in younger and elderly adults 
in the BNT162-01 and BNT162-02 trials (see the BNT162 IB), the BNT162b3 
doses planned in this trial in older adults are also expected to show measurable 
responses. These vaccines elicited measurable but lower responses in elderly 
adults than in younger adults, therefore, this trial includes the option to 
investigate BNT162b3 doses above the 30 µg BNT162b1/BNT162b2 doses 
already tested in elderly adults, to support any future Phase III program 
planned to support marketing approval (for details, see the BNT162 IB). This 
observation may indicate a lower innate immune activation capability of elderly, 
which in turn may mechanistically be associated with lower immunogenicity at 
dose levels that are immunogenic in the younger adults. 
− 
In this trial, the doses to be tested in older adults will only be tested if they have 
shown acceptable tolerability in younger adults. 
− 
The planned starting dose with BNT162b3 for older subjects aged 56 to 85 yrs 
in this trial will be ≤30% of a dose already shown to be acceptable in the 
subjects aged 18 to 55 years in this trial. 
− 
This trial includes age-appropriate inclusion/exclusion criteria to exclude 
potential risk factors relevant for all adults, but additional criteria have been 
included to further protect the safety of enrolled older adults. 
 The listed risks can be managed using routine symptom driven standard of care as 
described in Section 6.6.3. Treatment of these events is dependent on the 
discretion of the investigators. 
 Since this trial will involve the first immunization of humans with BNT162b3 vaccine, 
albeit not for the BNT162b vaccines, the trial subjects in Cohort 1 and other cohorts 
testing dose escalations, will be immunized using a sentinel dosing/staggering of 
subjects (EMA 2017 guidance “Strategies to Identify and Mitigate Risks for First-in-
Human and Early Clinical Trials with Investigational Medicinal Products”). 
To further ensure trial subject safety, the trial protocol foresees that: 
 On site observation periods after each immunization (i.e., 24 h for the first 
6 subjects per group and 6 h for other subjects in the same group) that are much 
longer than used in recently completed FIH clinical trials investigating related RNA-
based vaccines. For example, the two Moderna trials investigating mRNA vaccines 
against avian H10N8 and H7N9 influenza viruses in healthy adults (Feldman et al. 
2019) that observed trial subjects on site for only 1 h after each immunization before 
discharge from the trial site. Experience in the ongoing trials BNT162-01 and 
BNT162-02 has confirmed the adequacy of the implemented observations periods. 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 29 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
 More frequent on site visits after immunization (i.e., on Days 2 and 8) than used in 
recently completed FIH clinical trials investigating with related RNA-based vaccines, 
e.g., the two Moderna trials investigating mRNA vaccines against avian H10N8 and 
H7N9 influenza viruses in healthy adults (Feldman et al. 2019) that used on site 
visits on Day 8. 
 Subject wellbeing questioning by telephone at 48±2 h after each immunization 
(where applicable, after both the prime and boost immunizations) will be performed 
for the first 6 subjects per cohort. Additional subject wellbeing calls may be included 
at the discretion of the SRC. 
 In the case that an individual experiences dose limiting toxicities or that the 
frequency or pattern of AEs within a sub-cohort gives cause for concern, the 
investigator may request an ad hoc review by the SRC before further doses of a 
given vaccine construct are administered. 
 If the investigator considers necessary, the planned observation periods before 
proceeding to dose further subjects in the same group may be prolonged by 24 h. 
 The SRC must assess the safety and tolerability data of the first 6 subjects before 
allowing progression to the next cohort, per cohort/dose level. 
 After each assessment, the SRC may request a prolongation of the observation 
periods to up to Day 7 for later cohorts. 
SRC may make recommendations on increasing observation periods and additional 
subject wellbeing calls may be included at the discretion of the SRC. 
To ensure trial subject safety during the trial, their safety will be monitored from Visit 0 
(screening) until approximately 6 months after the last immunization. 
Vaccine-related enhanced disease has been reported in the literature from non-clinical 
studies investigating different vaccine formulations tested to prevent various coronavirus-
induced diseases. Such effects have not been documented so far for SARS-CoV-2. No 
data are currently available to exclude that BNT162 may cause enhanced disease in 
vaccinated subjects. 
The risks linked to the pandemic COVID-19 outbreak will be managed by requiring that the 
trial subjects: 
 Avoid contact with persons tested positive for SARS-CoV-2 antibodies or have an 
increased risk for infection during their participation in the trial. 
 Practice social distancing and follow good practices to reduce their chances of 
being infected or spreading COVID-19 during their participation in the trial. 
 Complete health status checks which include symptom-directed physical 
examinations, vital signs assessments, and clinical laboratory tests at the planned 
visit days. 
 Use the Subject Hotline to contact the trial site during their participation in the trial 
should they require guidance or should they experience any symptoms of illness. 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 30 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
The reporting of any symptoms of illness, e.g., enhanced respiratory disease or flu-
like symptoms, may trigger diagnostic measures at the discretion of the investigator. 
To minimize the risk to trial subjects in this trial, an SRC will regularly review and evaluate 
the safety and immunogenicity data. For details, see Section 10.1.5. 
2.3.2 Benefit assessment 
After participating in this trial, depending on the immunization regimen followed, some trial 
subjects should be immune against SARS-CoV-2 infection. 
There is an urgent need for the development of new prophylactic vaccines given the threat 
posed by the increasing number of globally distributed outbreaks of SARS-CoV-2 infection. 
The BioNTech platform of RNA-based vaccines being tested in this trial is especially 
attractive because it has the ability to deliver high numbers of vaccine doses rapidly in a 
single production campaign. This platform has the added advantage of not employing live 
virus and could therefore potentially be used for immunocompromised populations. 
By participating in this trial, the trial subjects will support the development of a prophylactic 
vaccine against SARS-CoV-2 infection. 
2.3.3 Overall benefit/risk conclusion 
Overall, the sponsor considers the benefit/risk ratio to be acceptable for a trial of this type. 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 33 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
o If approved by the SRC, the next planned escalation dose (see Table 1) in 
Cohort 2 may be initiated. The data assessed by the SRC comprises 48 h 
data for 6 subjects including observation on site, phone interview, vital signs, 
TEAEs, local reactions, blood/clinical laboratory data, and brief physical 
examination outcome. 
o Once dose escalation is approved, the planned dose de-escalations may 
also be initiated. 
For any subsequent dose escalation cohorts, the sentinel/subject staggering process will 
be as follows: 
 Two sentinel subjects will be dosed on one day (with intervals of at least 30 min 
between subjects). 
 If the dosing in these subjects was considered to be safe and well tolerated by the 
investigator after 24±2 h observation on site, a 4 further subjects will be dosed (with 
intervals of at least 30 min between subjects). 
 If the dosing in these 4 subjects was considered to be safe and well tolerated by the 
investigator based 48 h data (24±2 h observation on site and phone interview for 
assessment 48±2 h after immunization; in addition to the available 48 h data from 
the sentinel subjects): 
o The remaining 6 subjects in the group will be dosed (with intervals of at least 
30 min between subjects). 
o If approved by the SRC, the next planned escalation dose (see Table 1) may 
be initiated. The data assessed by the SRC comprises 48 h data for 
6 subjects (including observation on site, short summary of phone interviews 
[including statement about diary reports], vital signs, investigator reported 
local and systemic reactions, TEAEs, solicited local & systemic reactions, 
blood/clinical laboratory data, and brief physical examination outcome). 
The maximum allowed dose for each vaccine candidate is defined in the Table 1. 
For any dose de-escalation or dose-refinement cohorts in younger adults, i.e., cohorts with 
doses lower than previously tested. 12 subjects will be dosed using a subject staggering 
(6-6) process (with intervals of at least 30 min between subjects). The doses in these 
cohorts must be lower than doses that have shown acceptable tolerability in younger 
adults (based on the data from 12 subjects up until 48 h after the first dose). The same 
dose will not be administered twice, i.e., in two cohorts. 
Administration of the planned starting dose (3 to 10 µg) in older subjects (Cohort 8) may 
start once at least a 30 µg dose has shown acceptable tolerability in younger adults (based 
on the data from 12 subjects up until 48 h after the boost dose; including observation on 
site, short summary of phone interviews [including statement about diary reports], vital 
signs, investigator reported local and systemic reactions, TEAEs, local reactions, 
blood/clinical laboratory data, and brief physical examination outcome). The dose in 
Cohort 8 must also be confirmed by the SRC. 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 36 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
Fever of severe intensity was reported. Most AEs were managed with simple measures 
and resolved spontaneously. 
The doses planned in this trial reflect emerging clinical data from the ongoing BNT162-01 
and BNT162-02 trials with the related vaccine candidates BNT162b1 and BNT162b2 in 
younger adults (aged between 18 and 55 years) and elderly (adults aged between 65 and 
85 years). 
For the status and number of trial subjects dosed at least once with a BNT162b vaccine 
candidate in ongoing clinical trials, see the current BNT162 IB. 
See below for a summary and Section 2.1.3 for details. 
BNT162b1: 
 BNT162b1 P/B doses of 1, 10, 30, and 50 µg showed acceptable tolerability in 
younger adults. 
 Based on the tolerability profile after the prime dose at 60 µg (BNT162-01 trial) and 
100 µg (BNT162-02 trial), the respective boost doses were not administered. 
 BNT162b1 P/B doses of 10, 20, and 30 µg showed acceptable tolerability in elderly 
adults. This tolerability appears to be better than seen in younger adults at the same 
doses. 
BNT162b2: 
 BNT162b2 P/B doses of 1, 10, and 30 µg showed acceptable tolerability in younger 
adults. 
 BNT162b2 P/B doses of 10, 20, and 30 µg in elderly adults. This tolerability appears 
to be better than seen in younger adults at the same doses. 
 
Based on the BNT162b1 and BNT162b2 tolerability data summarized above, and the 
implemented safety measures (sentinel/staggered subject dosing, post-dose observations 
period, wellbeing questioning, etc.) as described in the section Risk assessment, the 
planned BNT162b3 doses in older adults in this trial are expected to show acceptable 
tolerability. 
Based on the available immunogenicity and CMI response data after dosing with 
BNT162b1 and BNT162b2 in younger and elderly adults in the BNT162-01 and 
BNT162-02 trials (see the BNT162 IB), the BNT162b3 doses planned in this trial in older 
adults are also expected to show measurable responses. The sponsor will continue to 
evaluate these emerging data from these ongoing studies to inform progression to 
discretionary dose levels. These vaccines elicited measurable but lower responses in 
elderly adults than in younger adults, therefore, this trial includes the option to investigate 
BNT162b3 doses above the 30 µg BNT162b1 / BNT162b2 doses already tested in elderly 
adults, to support any future Phase III program planned to support marketing approval. 
Altogether, the doses planned in older adults in this trial are considered adequate to 
support the trial objectives and to pose an acceptable risk to trial subjects. 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 37 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
Based on the available clinical and non-clinical data experience, the sponsor expects the 
planned maximal dose (see Table 1) to be safe. 
The planned starting dose with BNT162b3 for older subjects aged 56 to 85 years in this 
trial will be ≤30% of a dose already shown to be acceptable in the subjects aged 18 to 
55 years in this trial. Selection of a lower dose for the first dosing in older adults than found 
to be acceptable in younger adults reflects is considered good practice when progressing 
to new populations. The chosen cut-off, ≤30%, is a reflection of the 3-fold safety margin 
often used by the sponsor, but is otherwise arbitrary. 
Taken together, the planned starting dose in this trial with healthy subjects is considered to 
be safe, but still sufficient to induce an anti-viral immune response. 
4.4 
End of Treatment (EoT) and end of trial definition 
A trial subject is considered to have completed the trial if they have completed all planned 
visits as listed in the SoA, including all follow-up visits (see Section 1.3). The End of 
Treatment is defined as the date the last subject completed the EoT Visit (Visit 7). When 
entering the follow-up phase, i.e., after completing the EoT Visit, subjects are allowed to 
participate in other clinical trials. 
The end of trial is defined as the date when the last subject completed Visit 10 (Last 
Subject Last Visit). 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 38 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
5 
TRIAL POPULATION 
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, is not permitted. 
5.1 
Inclusion criteria 
5.1.1 Inclusion criteria Part A 
Volunteers are only eligible to be enrolled in the trial if they meet all of the following 
criteria: 
1. Have given informed consent by signing the informed consent form (ICF) before 
initiation of any trial-specific procedures. 
2. They must be willing and able to comply with scheduled visits, treatment schedule, 
laboratory tests, lifestyle restrictions (e.g., to practice social distancing and to follow 
good practices to reduce their chances of being infected or spreading COVID-19), and 
other requirements of the trial. 
3. They must be able to understand and follow trial-related instructions. 
4. For younger adult cohorts, volunteers must be aged 18 to 55 years, have a BMI over 
19 kg/m2 and under 30 kg/m2 (i.e., be neither underweight nor obese), and weigh at 
least 50 kg at Visit 0. 
5. OR 
6. For older adult cohorts, volunteers must be aged 56 to 85 years, have a BMI over 
19 kg/m2 and under 30 kg/m2 (i.e., be neither underweight nor obese), and weigh at 
least 50 kg at Visit 0. 
7. They must be healthy, in the clinical judgment of the investigator, based on medical 
history, physical examination, 12-lead ECG, vital signs (systolic/diastolic blood 
pressure, pulse rate, body temperature, respiratory rate), and clinical laboratory tests 
(blood chemistry, hematology, and urine chemistry) at Visit 0. 
8. Note: Healthy volunteers with pre-existing stable disease, defined as disease not 
requiring significant change in therapy or hospitalization for worsening disease during 
the 6 wks before enrollment, can be included. 
9. Women of childbearing potential (WOCBP) must have a negative beta-human 
chorionic gonadotropin urine test at Visit 0 and Visit 1. Women that are post-
menopausal or permanently sterilized will be considered as not having reproductive 
potential. 
10. WOCBP must agree to practice a highly effective form of contraception during the trial, 
starting after Visit 0 and continuously until 60 d after receiving the last immunization. 
WOCBP must agree to require their male partners to use condoms during sexual 
contact (unless male partners are sterilized or infertile). 
11. WOCBP must confirm that they practiced at least one highly effective form of 
contraception for the 14 d prior to Visit 0. 
12. WOCBP must agree not to donate eggs (ova, oocytes) for the purposes of assisted 
reproduction during trial, starting after Visit 0 and continuously until 60 d after receiving 
the last immunization. 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 39 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
13. Men who are sexually active with a WOCBP and have not had a vasectomy must 
agree to practice a highly effective form of contraception with their female partner of 
childbearing potential during the trial, starting after Visit 0 and continuously until 60 d 
after receiving the last immunization. 
14. Men must be willing to refrain from sperm donation, starting after Visit 0 and 
continuously until 60 d after receiving the last immunization. 
15. They must have confirmation of their health insurance coverage prior to Visit 0. 
16. They must agree to not be vaccinated during the trial, starting after Visit 0 and 
continuously until 28 d after receiving the last immunization. 
5.2 
Exclusion criteria 
5.2.1 Exclusion criteria Part A 
Volunteers are excluded from the trial if they meet or present any of the following criteria: 
1. Have had any acute illness, as determined by the investigator, with or without fever, 
within 72 h prior to the first immunization. An acute illness which is nearly resolved with 
only minor residual symptoms remaining is allowable if, in the opinion of the 
investigator, the residual symptoms will not compromise their wellbeing if they 
participate as trial subjects in the trial, or that could prevent, limit, or confound the 
protocol-specified assessments. 
2. Are breastfeeding on the day of Visit 0 or who plan to breastfeed during the trial, 
starting after Visit 0 and continuously until at least 90 d after receiving the last 
immunization. 
3. Have a known allergy, hypersensitivity, or intolerance to the planned IMP including any 
excipients of the IMP. 
4. Had any medical condition or any major surgery (e.g., requiring general anesthesia) 
within the past 5 years which, in the opinion of the investigator, could compromise their 
wellbeing if they participate as trial subjects in the trial, or that could prevent, limit, or 
confound the protocol-specified assessments. 
5. Have any surgery planned during the trial, starting after Visit 0 and continuously until at 
least 90 d after receiving the last immunization. 
6. Had any chronic use (more than 21 continuous days) of any systemic medications, 
including immunosuppressants or other immune-modifying drugs, within the 6 months 
prior to Visit 0 unless in the opinion of the investigator, the medication would not 
prevent, limit, or confound the protocol-specified assessments or could compromise 
subject safety. 
Note: Healthy participants with pre-existing stable disease, defined as disease not 
requiring significant change in therapy or hospitalization for worsening disease during 
the 6 wks before enrollment, can be included. 
7. Received any vaccination within the 28 d prior to Visit 0. 
8. Had administration of any immunoglobulins and/or any blood products within the 
3 months prior to Visit 0. 
9. Had administration of another IMP including vaccines within 60 d or 5 half-lives 
(whichever is longer), prior to Visit 0. 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 40 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
10. Have a known history or a positive test of any of HIV 1 or 2, Hepatitis B, or Hepatitis C, 
within the 30 d prior to Visit 0. 
11. Have a positive PCR-based test for SARS-CoV-2 within the 30 d prior to Visit 1. 
12. Have a positive drugs of abuse (for amphetamines, benzodiazepines, barbiturates, 
cocaine, cannabinoids, opiates, methadone, methamphetamines, phencyclidine, and 
tricyclic antidepressants) result at Visit 0 or Visit 1. 
13. Have a positive breath alcohol test at Visit 0 or Visit 1. 
14. Previously participated in an investigational trial involving lipid nanoparticles. 
15. Are subject to exclusion periods from other investigational trials or simultaneous 
participation in another clinical trial. 
16. Have any affiliation with the trial site (e.g., are close relative of the investigator or 
dependent person, such as an employee or student of the trial site). 
17. Have a history (within the past 5 years) of substance abuse or known medical, 
psychological, or social conditions which, in the opinion of the investigator, could 
compromise their wellbeing if they participate as trial subjects in the trial, or that could 
prevent, limit, or confound the protocol-specified assessments. 
18. Have a history of hypersensitivity or serious reactions to previous vaccinations. 
19. Have a history of Guillain-Barré Syndrome within 6 wks following a previous 
vaccination. 
20. Have a history of narcolepsy. 
21. Have history of alcohol abuse or drug addiction within 1 year before Visit 0. 
22. Have a history of or suspected immunosuppressive condition, acquired or congenital, 
as determined by medical history and/or physical examination at Visit 0. 
23. Have any abnormality or permanent body art (e.g., tattoo) that, in the opinion of the 
investigator, would obstruct the ability to observe local reactions at the injection site. 
24. Have had any blood loss >450 mL, e.g., due to donation of blood or blood products or 
injury, within the 7 d prior to Visit 0 or plan to donate blood during the trial, starting after 
Visit 0 and continuously until at least 7 d after receiving the last immunization. 
25. Symptoms of COVID-19, e.g., respiratory symptoms, fever, cough, shortness of breath 
and breathing difficulties. 
26. Have had contact with persons diagnosed with COVID-19 or who tested positive for 
SARS-CoV-2 by any diagnostic test within the 30 d prior to Visit 1. 
27. Are soldiers, persons in detention, CRO or sponsor staff or their family members. 
28. Regular receipt of inhaled/nebulized corticosteroids. 
29. Have a condition known to put them at high risk for severe COVID-19, including those 
with any of the following risk factors: 
o Cancer 
o COPD (chronic obstructive pulmonary disease) 
o Immunocompromised state (weakened immune system) from solid organ 
transplant 
o Obesity (BMI of 30 or higher) 
o Serious heart conditions, such as heart failure, coronary artery disease, or 
cardiomyopathies 
o Sickle cell disease 
o Diabetes mellitus 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 41 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
o Hypertension 
o Asthma 
o Chronic liver disease 
o Known Stage 3 or worse chronic kidney disease (glomerular filtration rate 
<60 mL/min/1.73 m2) 
o Anticipating the need for immunosuppressive treatment within the next 6 months 
o Resident in a long-term facility 
o Current vaping or smoking (occasional smoking is acceptable) 
o History of chronic smoking within the prior year 
5.3 
Lifestyle considerations 
Strenuous physical activity will not be allowed on visit days. When at the trial site, trial 
subjects will not be allowed to smoke or to drink alcohol. 
For Cohorts 1 and any subsequent dose escalation cohorts (in younger adults or older 
adults), the first 6 subjects dosed in each group will be required to remain at the site for 
approximately 24 h after the first immunization. The remaining trial subjects in these 
cohorts will be required to remain at the site for approximately 6 h after the first 
immunization. 
For any dose de-escalation or dose-refinement cohorts, i.e., cohorts with doses lower than 
previously found to be acceptable, trial subjects will be required to remain at the site for 
approximately 6 h after the first immunization. 
For all cohorts (irrespective of whether dose escalation, dose de-escalation, or dose-
refinement cohorts), all trial subjects will be required to remain at the site for 
approximately 6 h after the boost immunization. 
Trial subjects will be warned to avoid contact with persons tested positive for SARS-CoV-2 
antibodies or those who have an increased risk for infection. 
Trial subjects will be required to practice social distancing and to follow good practices to 
reduce their chances of being infected or spreading COVID-19, e.g., as described in the 
WHO guidance “Protection measures for persons who are in or have recently visited (past 
14 days) areas where COVID-19 is spreading” or regional equivalents. 
5.4 
Screen failures 
Screen failures are defined as individuals who consent to participate in the trial but who 
are not subsequently assigned to IMP. 
A minimal set of screen failure information is required to ensure transparent reporting of 
screening failures to meet the Consolidated Standards of Reporting Trials (CONSORT) 
publishing requirements and to respond to queries from regulatory authorities. Minimal 
information includes demography, date the ICF was signed, the reasons for screen 
failures, and any SAEs, if applicable. 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 42 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
6 
TRIAL TREATMENTS 
Trial treatment is defined as any IMP intended to be administered to a trial subject 
according to the trial protocol. Trial treatment must be administered by a physician. 
6.1 
IMP administered 
Name: 
BNT162b3 vaccine - Anti-viral RNA vaccine for active immunization against COVID-19. 
Type: 
RNA-LNP vaccine utilizing the BioNTech modRNA format: product code BNT162b3. 
Dosage levels: 
See Table 1. The planned dose per vaccine candidate will not exceed the pre-defined 
maximum dose (see Table 1). 
Dosage 
frequency: 
Two injections 21 d apart. Injection volumes will be up to 1.5 mL. 
Administration 
route: 
Intramuscular (IM); upper arm, musculus deltoideus. The same arm may be used for 
both immunizations. The non-dominant arm is preferred. 
6.2 
Preparation/handling/storage/accountability 
The preparation of solution for injection will be performed by aseptic handling procedures 
by pharmaceutical personnel or other trained personnel at the trial site. 
For instructions on IMP (BNT162 vaccine) preparation, handling, and storage, see the 
Pharmacy Manual. 
The investigator or a physician must confirm appropriate temperature conditions were 
maintained during transit for all trial intervention received and any discrepancies are 
reported and resolved before use of the trial intervention. 
Only trial subjects enrolled in the trial may receive IMP and only authorized site personnel 
may administer IMP. All IMP (and any components thereof) must be stored in a secure, 
environmentally controlled, and monitored (manual or automated) area in accordance with 
the labeled storage conditions with access limited to the investigator and authorized trial 
site personnel. 
The investigator, nominated site personnel, or the head of the site (where applicable) is 
responsible for IMP (and any components thereof) accountability, reconciliation, and 
record maintenance (i.e., receipt, reconciliation, and final disposition records). 
Further guidance and information for the final disposition of unused IMP (and any 
components thereof) is provided in the Pharmacy Manual. 
6.3 
Measures to minimize bias: randomization and blinding 
Not applicable. 
6.4 
Trial treatment compliance 
Trial subjects will be immunized by a physician. 
The date and time of each immunization must be recorded in the source documents and 
recorded in the case report form (CRF). The IMP dose and trial subject identification will 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 43 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
be confirmed at the time of administration by a member of the trial site personnel other 
than the person administering the IMP. 
6.5 
Concomitant therapy 
Any medication or vaccine (including over-the-counter or prescription medicines, vitamins, 
and/or herbal supplements, or other specific categories of interest) that the trial subject 
receives during the trial, i.e., starting after Visit 0 and until Visit 7, must be recorded along 
with the: 
 Reason for use 
 Dates of administration including start and end dates 
 Dosage information including dose and frequency 
Record any vaccination, including SARS-CoV-2 vaccination, received after the EoT Visit 
until the last FU Visit (Visit 10) in the CRF. 
The sponsor’s Medical Monitor should be contacted if there are any questions regarding 
concomitant or prior therapy. 
Trial subjects must abstain from taking prescription or non-prescription drugs (including 
vitamins and dietary or herbal supplements), unless, in the opinion of the investigator and 
sponsor, the medication will not compromise their wellbeing, or could prevent, limit, or 
confound the protocol-specified assessments. 
Trial subjects are required to agree to not be vaccinated during the trial, starting after 
Visit 0 and continuously until 28 d after receiving the last immunization (see the inclusion 
criterion 16). 
Paracetamol/acetaminophen at doses of up to 4 g/day is permitted for use any time during 
the trial. Other concomitant medication may be considered on a case-by-case basis by the 
investigator, if required after consultation with the sponsor’s Medical Monitor. 
6.5.1 Premedication 
Not applicable. 
6.5.2 Rescue medication 
Not applicable. 
6.6 
Dose modifications 
The trial design allows for a flexible dosing which allows a better evaluation on the optimal 
dose range. For details, see Section 4.1. 
The decision to make dose adaptions or to initiate a cohort, will be made based on 
emerging data from this and other ongoing studies with related vaccine constructs. Dose 
escalation decisions will be validated by the SRC (for details, see Section 10.1.5); any plan 
to exceed the planned dose escalations will only be implemented after relevant approval of 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 44 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
a substantial protocol amendment. Dose de-escalation and escalation rules have been 
defined in this protocol (see Section 6.6.2). 
6.6.1 Dose limiting toxicity 
During the time of enrollment into a given dose escalation cohort in Part A, if any of the 
following events occur, it will be considered an individual dose limiting toxicity and further 
dosing in that cohort will be stopped: 
 Anaphylactic reaction considered related. 
 Generalized urticaria considered related. 
 Four trial subjects in that cohort with any severe unsolicited local event, if 
considered related and not manageable with simple measures (e.g., cooling, 
analgesia, nonsteroidal anti-inflammatory drugs [NSAIDs]). 
 AEs within 7 days of vaccination assessed by the investigator to be potentially life-
threatening (Grade 4) and that are possibly related, or for which there is no 
alternative, plausible, attributable cause. 
 Any systemic SAE within 7 days of vaccination that is assessed by the investigator 
as possibly related, or for which there is no alternative, plausible, attributable cause. 
 Any fever >40.0°C (>104.0°F) within 7 days of vaccination considered related and 
confirmed by an investigator or medically qualified person. 
 Two trial subjects (at any dose level) with the same or similar severe (Grade 3 or 
higher) AE or reactogenicity (including clinically significant laboratory abnormalities) 
within 7 days of vaccination, considered related, or for which there is no alternative, 
plausible, attributable cause (for severity grading of AEs see Section 10.3.1.7). 
Approval from the SRC will be required prior to any further dosing in the affected cohort. 
The SRC may call for the opening of a lower dose level cohort. 
The same events will prompt IMP discontinuation for individual subjects as described in 
Section 6.6.4. Tasks connected to the discontinuation of IMP are described in Section 7.1. 
The above guidance regulates how potential dose limiting toxicities may influence the 
decisions to further enroll trial subjects in any cohort. These decisions are taken by the 
SRC based on the 48 h safety data from the first 6 subjects of each cohort (see 
Section 4.1). Due to the staggered sentinel dosing design, subjects will have been 
followed for 4 d for the sentinel subjects when this SRC decision is made. 
The above guidance also regulates how potential dose limiting toxicities may influence the 
decisions to enroll subjects into the next cohort for that vaccine, i.e., to progress to the 
next cohort. These decisions are taken by the SRC based on the 48 h safety data from all 
12 subjects of each cohort (see Section 4.1). Due to the staggered sentinel dosing design, 
subjects will have been followed for 6 d for the sentinel subjects when this SRC decision is 
made. 
The sum of the above events occurring at any time during the trial conduct (i.e., not just 
with 7 days of vaccination) will be used for the overall assessment of the candidate 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 45 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
vaccine safety profile, i.e., to assess whether any of the observed side effects are possibly 
linked to vaccination. 
The assessment of dose limiting toxicity should be done consistently for all subjects 
treated with the same treatment and dose. 
In addition to data entry in the CRF, DLTs will be reported within 24 h via SAE Report 
Form as described in Section 10.3.1.10 and forwarded to the safety contacts listed in the 
same section. 
6.6.2 Dose modification guidance/rules 
Part A 
See Section 10.1.5 for the data set upon which SRC decisions described below are made 
for Part A. 
 Any proposal to alter a planned escalation dose, or test a lower dose required for 
safety de-escalation must be approved by the SRC. 
 Any plan to exceed the planned maximum dose will only be implemented after 
relevant approval of a substantial protocol amendment. 
Dose escalation: 
 Dose escalation will only continue if the previous dose was considered safe and well 
tolerated by the SRC. 
 Any proposed alteration to the planned escalation dose level to a smaller or larger 
escalation increment than that shown in Table 1 must be approved by the SRC. 
 Any proposal to exceed the planned maximum dose for the trial will only be 
implemented after relevant approval of a substantial amendment. 
6.6.3 Mitigation plans for specific AEs 
Based on experience with other BioNTech RNA-based vaccines and published data from 
other RNA-based vaccines, it is anticipated that subjects may experience TEAEs of flu-like 
symptomatology following the administration of RNA vaccines due to the mechanism of 
action of RNA vaccines. This may include fever, chills, rigors, tachycardia, arthralgia, 
myalgia, headache, nausea. Treatment of these events is dependent on the discretion of 
the investigators; however, the following management suggestions are provided: 
 Treat fever with acetaminophen or NSAIDs with a dose per trial site 
recommendation. 
 After the first occurrence of flu-like symptomatology, subjects can be treated with 
standard therapeutic dose of acetaminophen, or NSAIDs, starting at least 2 h after 
the immunization. 
 Corticosteroids should be avoided as either prophylaxis or treatment as it 
counteracts the effects of immunization. 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 46 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
 Ensure adequate hydration of trial subjects on the day of immunization. Consider 
administering fluids (e.g., water for drinking, 0.5 to 1.0 L) within approximately 2 h 
following the immunization per trial site standard. 
If subjects experience enhanced respiratory disease or progression of flu-like 
symptomatology, such as non-resolution of the symptoms after 7 d, symptom kinetics that 
are inconsistent with a relationship to RNA immunization, additional diagnostic measures 
should be considered and the Medical Monitor should be informed. 
6.6.4 Safety stopping criteria 
See Section 6.6.1 for the list of events that must prompt discontinuation for the individual 
subjects. 
The SRC will review and evaluate the collected safety data periodically during the trial (see 
Section 10.1.5 for details). A decision to stop treatment for an individual subject or to 
terminate the trial may be taken if safety concerns are identified by the SRC. 
Suspected unexpected serious adverse reactions (SUSARs) will immediately be reviewed 
by the SRC. They will trigger a temporary stop of IMP administration to new subjects in the 
respective dose level cohort until the SRC recommendation to continue or to permanently 
stop IMP administration of new subjects in the respective dose level cohort. 
Guidance for discontinuation of trial treatment is provided in Section 7.1. 
6.7 
Treatment after the end of the trial 
Not applicable. 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 47 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
7 
DISCONTINUATION OF TRIAL TREATMENT AND TRIAL 
SUBJECT DISCONTINUATION/WITHDRAWAL 
7.1 
Discontinuation of trial treatment 
In rare instances, it may be necessary for a trial subject to permanently discontinue IMP 
administration (i.e., to not receive the boost dose for groups with P/B regimens). If IMP 
administration is definitively discontinued, the trial subject will remain in the trial to be 
evaluated for safety. 
IMP administration must be stopped if dose limiting toxicities described in Section 6.6.1 
are observed. 
If any of the above are observed, an unscheduled safety analysis by the SRC will be 
required. Trial subjects who tolerated initial vaccinations will be allowed to receive a 
second vaccination during this time. 
In the event of discontinuation of trial treatment, it must be documented on the appropriate 
CRF/in the medical records whether the participant is discontinuing further receipt of trial 
treatment or also from trial procedures, post-treatment follow-up, and/or future collection of 
additional information. 
Trial subjects permanently discontinued from IMP administration should still complete all 
assessments planned in the SoA (Section 1.3). 
7.1.1 Temporary discontinuation 
Not applicable. 
7.1.2 Rechallenge 
Not applicable. 
7.2 
Trial subject discontinuation/withdrawal from the trial 
A trial subject may withdraw from the trial at any time at his/her own request, or may be 
withdrawn at any time at the discretion of the investigator for safety, behavioral, 
compliance, or administrative reasons. Withdrawals are expected to be uncommon. 
If the trial subject withdraws consent for data processing, the sponsor may retain and 
continue to use any data collected before such a withdrawal of consent. 
If a trial subject withdraws from the trial, he/she may request destruction of any samples 
taken and not tested, and the investigator must document sample destruction in the 
Investigator’s Site File (ISF). 
If the trial subject withdraws consent or is permanently discontinued from the trial, the trial 
subject will be permanently discontinued both from IMP administration and from the trial at 
that time. 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 48 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
If possible, permanently discontinued trial subjects will: 
 Complete all assessments planned for that visit and for the EoT Visit (Visit 7), if 
discontinued on a visit day. 
 Complete all assessments planned for the EoT Visit (Visit 7), if not discontinued on 
a visit day. 
7.3 
Lost to follow-up 
A trial subject will be considered lost to follow-up if they repeatedly fail to return for 
scheduled visits and is unable to be contacted by the trial site. 
The following actions must be taken if a trial subject fails to return to the trial site for a 
required trial visit: 
 The trial site must attempt to contact the trial subject and reschedule the missed 
visit as soon as possible and counsel the trial subject on the importance of 
maintaining the assigned visit schedule and ascertain whether or not the trial 
subject wishes to and/or should continue in the trial. 
 Before a trial subject is deemed lost to follow-up, the investigator or designee must 
make every effort to regain contact with the trial subject (where possible, three 
telephone calls and, if necessary, a certified letter to the trial subject’s last known 
mailing address or local equivalent methods). These contact attempts should be 
documented in the trial subject’s medical record. 
 If the trial subject continues to be unreachable, they will be considered to have 
withdrawn from the trial. 
7.4 
Replacement of permanently discontinued trial subjects 
Permanently discontinued trial subjects will be replaced to ensure that the 12 subjects 
complete the trial as planned up to Visit 3 for each group unless permanently discontinued 
due to safety issues; in the latter cases, the SRC will decide whether to replace the 
discontinued trial subjects. Trial subjects permanently discontinued after Visit 3 will not be 
replaced. 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 49 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
8 
TRIAL ASSESSMENTS AND PROCEDURES 
See the SoA (Section 1.3) for all planned time points for assessments. 
Protocol waivers or exemptions are not allowed. 
Immediate safety concerns should be discussed with the sponsor immediately upon 
occurrence or awareness to determine if the trial subject should continue or discontinue 
IMP administration (i.e., to administer the boost administration for groups with the P/B 
regimen). 
Adherence to the trial protocol requirements, including those specified in the SoA, is 
essential and required for trial conduct. 
All screening evaluations must be completed and reviewed to confirm that potential trial 
subjects meet all eligibility criteria. The investigator will maintain a screening log to record 
details of all trial subjects screened and to confirm eligibility or record reasons for 
screening failure, as applicable. 
For the baseline assessments (demographics, medical history), see Section 10.12. 
8.1 
Efficacy assessments 
Not applicable. 
8.2 
Safety assessments 
Planned time points for all safety assessments are provided in the SoA (Section 1.3). 
8.2.1 Physical examinations 
Complete physical examinations will be performed at screening. Brief physical 
examinations will be performed at later time points including prior boost immunizations 
(see the SoA in Section 1.3). 
 A complete physical examination will include, at a minimum, assessments of the 
cardiovascular, respiratory, gastrointestinal, and neurological systems. Height (in 
cm) will also be measured and recorded during complete physical examinations. 
 A brief (symptom-directed) physical examination. The brief physical examination 
includes an overall health judgment. In-depth physical examinations are required if 
obvious pathological signs are visible or in the case the subject states any signs or 
symptoms. 
8.2.2 Vital signs 
Body temperature (in °C), pulse rate, respiratory rate, and blood pressure will be assessed 
at the times given in the SoA (Section 1.3). Body weight (in kg) will also be measured and 
recorded. 
Blood pressure (systolic/diastolic, in mmHg) and pulse (in bpm) measurements will be 
assessed while the trial subject is in a supine position/at rest. If available, a completely 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 50 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
automated device should be used, otherwise manual techniques can be used. The same 
method of measurement should be used for the trial subject during the course of the trial. 
Blood pressure and pulse measurements should be preceded by at least 5 min of rest for 
the trial subject in a quiet setting without distractions (e.g., television, cell phones). 
Vital signs should be taken before any blood collection. 
8.2.3 Electrocardiograms 
Standard 12-lead ECGs will be recorded at the times given in the SoA (Section 1.3) using 
an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, 
and corrected QT (QTc; according to Bazett) intervals. 
ECGs will be judged by the investigator as clinically significant (yes/no); only the 
investigator assessment and heart rate will be recorded in the CRF. 
8.2.4 Clinical laboratory tests 
See Section 10.2 for the list of clinical laboratory tests to be performed at the times given 
in the SoA (Section 1.3). 
The investigator must review the laboratory report, document this review with signature 
and date, and record any clinically relevant changes occurring during the trial in the AE 
section of the CRF. The laboratory reports must be filed with the source documents. 
All laboratory tests with values considered clinically significantly abnormal during 
participation in the trial should be repeated until the values return to normal or baseline or 
are no longer considered clinically significant by the investigator or the sponsor’s Medical 
Monitor. 
If such values do not return to normal/baseline within a period of time judged reasonable 
by the investigator, the etiology should be identified and the sponsor notified. 
All protocol-required clinical laboratory tests (see Section 10.2) must be conducted in 
accordance with the trial site standard. 
If laboratory values from non-protocol-specified laboratory assessments performed at the 
laboratory require a change in trial subject management or are considered clinically 
significant by the investigator (e.g., SAE, AE or dose modification), then the results must 
be recorded in the CRF. 
8.2.5 Drugs of abuse screening 
Screening for drugs of abuse (amphetamines, benzodiazepines, barbiturates, cocaine, 
cannabinoids, opiates, methadone, methamphetamines, phencyclidine, and tricyclic 
antidepressants) will be performed using a commercially available kit at the times given in 
the SoA (Section 1.3). 
8.2.6 Testing for alcohol use 
Breath testing for alcohol use will be performed at the times given in the SoA (Section 1.3). 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 51 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
8.2.7 Viral screening (for blood-borne viruses) 
The screen will test for: Hepatitis B surface antigen, Hepatitis B core antibody, Hepatitis C 
antibodies, and HIV-1 and HIV-2 antibodies. For SARS-CoV-2 testing, see Section 8.2.10. 
8.2.8 Subject diaries 
Trial subjects will be given subject diaries at Visit 1 and be asked to record any AEs 
between visits, solicited local reactions at the injection site (pain, tenderness, 
erythema/redness, induration/swelling), and solicited systemic reactions (nausea, 
vomiting, diarrhea, headache, fatigue, myalgia, arthralgia, chills, loss of appetite, malaise, 
and fever [i.e., ≥38°C]). 
Subject diaries may include App-supported electronic documentation in compliance with 
the applicable data protection regulations. 
Trial site personnel will collect subject diaries at the visits given in the SoA (Section 1.3). 
8.2.9 Assessment of local reactions 
Local reactions after IM immunization will be assessed by the investigator at the times 
given in the SoA (Section 1.3). This information will be used to validate the solicited 
assessment of local reactions in the subject diary and potentially support AE reporting. 
Local reactions (via daily solicited reports in the subject diaries and as assessed on visit 
days by the investigator) will be graded based on the guidance given in the US FDA 
Guidance for Industry “Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers 
Enrolled in Preventive Vaccine Clinical Trials” for “local reaction to injectable products” 
(see the section “Assessment of intensity” in Section 10.3.1.11). The reporting of local 
reactions will be based on the subject’s assessments only. 
8.2.10 SARS-CoV-2 testing 
SARS-CoV-2 testing (PCR-based and antibody-based) will be performed at the time points 
provided in the SoA (Section 1.3). 
This includes PCR-based testing for SARS-CoV-2 as an eligibility criterion and blood 
draws for anti-SARS-CoV-2 antibody testing as baseline reference for immunogenicity 
analysis. 
If required, this reference will allow the discrimination between vaccinated and infected 
subjects. 
The screen for SARS-CoV-2 by PCR-based test using oral swipe sample can be 
performed by either a central laboratory or a “point of care” device at the trial site. 
 If a central laboratory is used: Only the SARS-CoV-2 status will be tested and no 
further data will be generated. 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 52 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
 If a point of care device is used: The most commonly used devices come with pre-
defined test panels that test for a range of pathogens and not just for SARS-CoV-2. 
Thus, inevitably and automatically, incidental data for the pathogens other than 
SARS-CoV-2 will be generated when using such devices. Since this incidental data 
is not required by this trial, only the results for SARS-CoV-2 will be recorded in the 
CRF, analyzed, and reported as described in this protocol. If a test result for 
SARS-CoV-2 or another pathogen must be reported to relevant authorities, this 
notification will be done by the trial site. 
The anti-SARS-CoV-2 antibody testing will be performed with a commercially available 
antibody test. In case this commercial antibody test can, discriminate between vaccine-
specific and infection-specific antibody responses (based on the antigens used), it will be 
used to test subjects who may have experienced enhanced respiratory disease or 
progression of flu-like symptomatology, such as non-resolution of the symptoms after 7 d, 
symptom kinetics that are inconsistent with a relationship to RNA immunization, as might 
be expected with a COVID-19 disease (see Section 6.6.3). 
In these cases, ad hoc anti-SARS-CoV-2 antibody testing will be performed to test for the 
development and presence of SARS-CoV-2-specific antibodies, ideally at approximately 
14 d and 28 d after the last immunization with the BNT162 candidate vaccine. This data 
will be used to evaluate the development and progression of an antibody response 
allowing the diagnosis of a manifest infection. 
In case this commercially available test cannot discriminate between vaccine-specific and 
infection-specific antibody responses, the same kind of analysis will be performed with a 
custom-made assay specifically developed by the CRO. 
8.2.11 Subject hotline 
Subjects will be provided with contact details for a Subject Hotline, which can be used to 
contact the trial site during their participation in the trial should they require guidance or 
should they experience any symptoms of illness. The reporting of any symptoms of illness, 
e.g., flu-like symptoms, may trigger diagnostic measures (including ad hoc site visits) at 
the discretion of the investigator. For guidance for specific AEs, see Section 6.6.3. 
8.2.12 Subject wellbeing questioning 
Structured non-leading subject wellbeing questioning will be performed at the time given in 
the SoA (Section 1.3). Subject responses may trigger more in-depth questioning on 
specific topics, and may trigger diagnostic measures (including ad hoc site visits) at the 
discretion of the investigator. 
8.2.13 Assessment of systemic reactions 
Systemic reactions after IM immunization will be assessed via daily solicited reports in the 
subject diaries and at the times given in the SoA (Section 1.3). 
 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 53 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
Systemic reactions will be graded using criteria based on the guidance given in US FDA 
Guidance for Industry “Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers 
Enrolled in Preventive Vaccine Clinical Trials” for “systemic reaction grading scale” (see 
the section “Assessment of intensity” in Section 10.3.1.11). 
8.3 
Adverse events and serious adverse events 
The investigator and any qualified designees are responsible for detecting, documenting, 
and recording events that meet the definition of an AE or SAE and remain responsible for 
following up all AEs and SAEs. 
8.3.1 Time period and frequency for collecting AE and SAE information 
All AEs and SAEs will be collected from the date of subject consent until Visit 7; after 
Visit 7 (at Visits 8 and 9), only IMP-related AEs and SAEs will be collected. 
All SAEs (initial and follow-up reports) will be recorded and reported to the sponsor or 
designee within 24 h after becoming aware of the event, as indicated in Section 10.3.1.10. 
Investigators are not obligated to actively seek AEs or SAEs between Visit 9 and Visit 10 
and after conclusion of the trial participation. However, if the investigator learns of any 
SAE, including a death, at any time after a trial subject has been discharged from the trial, 
and he/she considers the event to be reasonably related to the IMP administration or trial 
participation, the investigator must promptly notify the sponsor. 
8.3.2 Method of detecting AEs and SAEs 
The method of recording, evaluating, and assessing causality of AEs and SAEs and the 
procedures for completing and transmitting SAE reports are provided in Section 10.3. 
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open-ended 
and non-leading verbal questioning of the trial subject is the preferred method to inquire 
about AE occurrences. 
8.3.3 Follow-up of AEs and SAEs 
After the initial AE/SAE report, the investigator is required to proactively follow each trial 
subject at subsequent visits/contacts. All AEs/SAEs/dose limiting toxicities (DLTs) will be 
followed until resolution, stabilization, the event is otherwise explained, or the trial subject 
is lost to follow-up (as defined in Section 7.3). Further information on follow-up procedures 
is provided in Section 10.3.1.7. 
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by the sponsor 
to elucidate the nature and/or causality of the AE or SAE as fully as possible. This may 
include additional laboratory tests or investigations, histopathological examinations, or 
consultation with other healthcare professionals. 
New or updated information will be recorded in the originally completed CRF. 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 54 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
The investigator will submit any updated SAE data to the sponsor within 24 h of receipt of 
the information as indicated in Section 10.3.1.10. 
All ongoing AEs/SAEs will be followed until resolution, considered by the investigator to be 
stable or chronic (resolved with sequelae), the trial subject is lost to follow-up or the trial 
subject withdraws consent. If no final status is reached by the time of Visit 9, the 
investigator must confirm the unavailability of a final status. 
8.3.4 Regulatory reporting requirements for SAEs 
Prompt notification of an SAE by the investigator to the sponsor is essential so that legal 
obligations and ethical responsibilities towards the safety of trial subjects and the safety of 
a trial treatment under clinical investigation are met. 
The sponsor has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a trial treatment under clinical investigation. The 
sponsor will comply with country-specific regulatory requirements relating to safety 
reporting to the regulatory authority, IECs, and investigators. The execution of expedited 
reporting to the different entities may be delegated as detailed in the trial Safety 
Management Plan. 
Safety reports will be prepared for SUSARs according to local regulatory requirements and 
sponsor policy and forwarded to investigators as necessary. 
For the IMP, it is the sponsor’s or delegate’s responsibility to perform SUSAR reporting to 
the regulatory authority, the IEC, and the other investigators as required by national law 
and applicable guidelines. 
An investigator who receives an investigator safety report describing an SAE or other 
specific safety information (e.g., summary or listing of SAEs) from the sponsor should 
review it and then file it together with the IB. If required by local requirements, the 
investigator will notify the relevant IEC. 
8.3.5 Pregnancy 
For WOCBP, urine pregnancy tests will be performed using a commercial kit at the times 
given in the SoA (see Section 1.3). 
Pregnancy information will only be collected after obtaining written informed consent from 
the pregnant female subject (or if a male subjects’ partner becomes pregnant, written 
informed consent from both). 
Pregnancy information will be collected for pregnancies that occurred after the date of the 
first dose of trial treatment until 60 d after the last dose of trial treatment for pregnant 
subjects (or until 60 d after the last immunization of the male subject for pregnant female 
partners). 
If a pregnancy is reported, the investigator should inform the sponsor within 24 h of 
learning of the pregnancy and should follow the procedures outlined in Section 10.4. 
Abnormal pregnancy outcomes (e.g., spontaneous abortion, fetal death, stillbirth, 
congenital anomalies, ectopic pregnancy) are considered SAEs. 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 55 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
8.3.6 Death events 
Any death that occurs within the observation period will be reported as an SAE. 
In case of a fatal event, the event term should not be “death” but the underlying event 
which led to death (death = outcome). If there is more than one AE in a fatal case, only for 
the AE leading to death the outcome “fatal” should be selected. If the cause of death is 
unknown and cannot be ascertained at the time of reporting, “unexplained death” should 
be documented as event term. 
8.3.7 Disease-related events and/or disease-related outcomes not qualifying 
as AEs or SAEs 
Not applicable, this trial will only enroll healthy trial subjects. 
8.3.8 Adverse events of special interest 
Enhanced respiratory disease or flu-like symptomatology not resolved after 7 d or with 
symptom kinetics that are inconsistent with a relationship to RNA immunization will 
considered AEs of special interest. 
8.4 
Treatment of overdose 
Any dose of trial treatment above the planned dose specified in this protocol will be 
considered an overdose. 
The sponsor does not recommend specific treatment for an overdose. 
In the event of an overdose, the investigator should: 
 Contact the sponsor’s Medical Monitor immediately. 
 Closely monitor the trial subject for any AE/SAE and laboratory abnormalities (at 
least for 7 d). 
 Document the quantity of the excess dose as well as the duration of the overdose in 
the CRF. 
Decisions regarding dose interruptions or modifications will be made by the investigator in 
consultation with the sponsor’s Medical Monitor based on the clinical evaluation of the trial 
subject. 
8.5 
Pharmacokinetics 
Not applicable. 
8.6 
Pharmacodynamics 
Not applicable. 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 58 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
9 
STATISTICAL CONSIDERATIONS 
9.1 
Statistical hypotheses 
There is no formal statistical hypothesis under test. 
9.2 
Sample size determination 
No formal sample size calculations were performed. 
For Part A, the inclusion of 12 subjects per group is considered to be adequate for a safety 
assessment of vaccine per dose level. The probability to observe a particular TEAE with 
incidence of 15% at least once in 12 subjects per group is 85.8%. 
9.3 
Analysis sets 
The following analyses sets are defined: 
Analysis set 
Description 
Screened Set 
All subjects who signed informed consent. 
Safety Set 
All subjects who received at least one dose of IMP. 
 
9.4 
Statistical analyses 
Statistical analyses will be performed by BioNTech or a designated CRO. All statistical 
analyses will be carried out using SAS®, Version 9.3 or higher, and/or other statistical 
software as required. 
The statistical analysis plan (SAP) will be finalized prior to database snapshot for the 
primary analysis and it will include a more technical and detailed description of the 
statistical analyses described in this section. Any deviations from the planned analyses 
described in the final SAP will be described and justified in the clinical trial report. 
This section gives a summary of the planned statistical analyses of the most important 
endpoints including primary and key secondary endpoints. 
9.4.1 General considerations 
In general, data will be summarized by groups and groups may be combined as 
appropriate. 
Continuous variables will be summarized by group using the following descriptive 
statistics: number of subjects (n), mean, standard deviation, median, minimum, and 
maximum. 
Categorical variables will be summarized by group presenting absolute and relative 
frequencies (n and %) of subjects in each category. 
Baseline is defined as last available value prior to first dose of IMP. 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 59 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
9.4.2 Primary endpoints 
The primary endpoints are defined in Section 3. 
All AEs will be coded using the most recent version of Medical Dictionary for Regulatory 
Activities (MedDRA®) coding system to get a system organ class (SOC) and preferred 
term (PT) for each AE. 
Solicited local and systemic reactions (from the diary card) will be summarized using the 
Safety Set. In general, solicited reactions will be analyzed by dose level and for each 
immunization, i.e.: 
 For the prime immunization up to 7 d after prime immunization 
 For the boost immunization up to 7 d after boost immunization 
For each immunization, the number and percentage of subjects reporting at least one local 
reaction or systemic reaction (i.e., solicited data collected using subject diaries) will be 
summarized for each of the following types using the Safety Set: 
 Any local reactions or systemic reactions 
 Grade ≥3 local reactions or systemic reactions 
Moreover, the number and percentage of subjects reporting at least one local reaction will 
be summarized by worst grade using the Safety Set. 
Treatment emergent AEs (TEAEs) are defined in Section 10.3.1 and will be summarized 
using the Safety Set. In general, AEs will be analyzed by dose level and for each 
immunization, i.e.: 
 For the prime immunization up to 28 d after prime immunization or until boost 
immunization (whichever comes first) 
 For the boost immunization up to 28 d after boost immunization 
 For the prime immunization up to 28 d after boost immunization 
Additionally, AEs will be summarized for all dose levels combined for each type. Additional 
AE analyses may be described in the SAP. 
For each analysis, the number and percentage of subjects reporting at least one TEAE will 
be summarized by PT nested within SOC for each of the following AE types using the 
Safety Set: 
 Any AE 
 Any AE excluding AEs based on solicited reporting via subject diaries 
 Related AE 
 Grade ≥3 AE 
 Related Grade ≥3 AE 
 Any SAE 
 Related SAE 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 60 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
Moreover, the number and percentage of subjects with any AE will be summarized by 
worst grade by PT nested within SOC. 
The analysis of AEs and local and systemic reactions may be repeated with a reduced set 
of terms, to enable like-for-like evaluations when these data are informally set alongside 
the data from other trials in the clinical development program for BNT162 vaccines. 
9.4.3 Secondary endpoints 
The secondary endpoints are defined in Section 3. 
The binary secondary endpoints will be summarized by group presenting absolute and 
relative frequencies (n and %) of subjects in each category for each assessment. The 
continuous secondary endpoints will be summarized by group using summary statistics. 
The scheduled time points for assessment are given in the SoA (see Section 1.3). 
9.4.4 Exploratory endpoints 
The exploratory endpoints are defined in Section 3. Exploratory analyses will be described 
in the SAP. 
9.4.5 Other safety analyses 
Safety data other than AEs that will be summarized includes clinical laboratory 
parameters, vital signs, and ECGs. All safety analyses will be based on the Safety Set and 
will be summarized descriptively by group unless otherwise stated. 
Clinical laboratory parameters 
The clinical laboratory parameters to be summarized and assessed are listed in 
Section 10.2. The scheduled time points for assessment are given in the SoA (see 
Section 1.3). 
Clinical laboratory parameters at each time point and change from baseline to each post-
baseline time point will be summarized using descriptive summary statistics for each 
parameter by group. 
Shift tables from baseline to worst intensity grade will be provided for each laboratory 
parameter by group. 
Additionally, the occurrence of clinically significant abnormal laboratory results within a trial 
subject will be analyzed using descriptive summary statistics for each parameter and visit 
by group. 
Abnormal laboratory results will be graded using criteria based on the guidance given in 
US FDA Guidance for Industry “Toxicity Grading Scale for Healthy Adult and Adolescent 
Volunteers Enrolled in Preventive Vaccine Clinical Trials” (see Section 10.3.1.11). 
Laboratory parameter results will be listed along with the normal ranges. Values that are 
below or above the normal ranges will be flagged. 
Clinical laboratory analysis details will be described in the SAP. 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 61 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
Vital signs 
The vital sign parameters to be summarized and assessed are given in Section 8.2.2. The 
scheduled time points for assessment are given in the SoA (see Section 1.3). 
Vital sign parameters at each time point and change from baseline to each post-baseline 
time point will be summarized using descriptive summary statistics for each parameter by 
group. 
ECG 
ECG parameters to be summarized and assessed are given in Section 8.2.3. The 
scheduled time points for assessment are given in the SoA (see Section 1.3). 
ECGs will be judged by the investigator as clinically significant (yes/no). 
9.4.6 Other analyses 
Other analyses will be described in the SAP. 
9.5 
Interim analyses 
The final analysis will be performed once all subjects have completed the EoT Visit 
(Visit 7). An analysis update will be performed once all subjects will have completed 
Visit 10. No formal interim statistical analysis will be performed. However, the preliminary 
analyses may be performed for each cohort once subjects within a cohort will have been 
followed up for at least 7 d following the dose. 
9.6 
Data monitoring committee 
An DMC is not planned. An SRC is planned, for details see Section 10.1.5. 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 62 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
10 
SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS 
10.1 
Regulatory, ethical, and trial oversight considerations 
This trial will be conducted in according to this protocol, the ethical principles that have 
their origin in the Declaration of Helsinki, Good Clinical Practice (GCP), and applicable 
regulatory requirements. 
10.1.1 Regulatory and ethical considerations 
This trial will be conducted in accordance with the protocol and with the following: 
 Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical 
Sciences (CIOMS) International Ethical Guidelines 
 Applicable GCP Guidelines 
 Applicable laws and regulations 
The protocol, protocol amendments, ICF, IB, and other relevant documents (e.g., 
advertisements) must be submitted to an IEC and reviewed and approved by the IEC 
before the trial is initiated. 
Any amendments to the protocol will require IEC approval before implementation of 
changes made to the trial design, except for changes necessary to eliminate an immediate 
hazard to trial subjects. 
The coordinating investigator or delegate will be responsible for the following: 
 Providing written summaries of the status of the trial to the IEC annually or more 
frequently in accordance with the requirements, policies, and procedures 
established by the IEC. 
 Notifying the IEC of SAEs or other significant safety findings as required by IEC 
procedures. 
 Providing oversight of the conduct of the trial at the site and adherence to 
requirements of ICH guidelines, the IEC, European regulation 536/2014 (if 
applicable), and all other applicable local regulations. 
The principal investigator, any investigator(s), the sponsor, or personnel at other 
establishments must cooperate with any inspection of the documents, facilities, records, 
and other resources deemed appropriate by the inspecting authorities to be related to the 
trial and that may be located at the trial site, at the sponsor, or at other establishments. 
The sponsor must be notified as soon as possible about any upcoming regulatory authority 
inspection. 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 63 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
10.1.2 Financial disclosure 
All investigators will provide the sponsor with sufficient, accurate financial information as 
requested to allow the sponsor to submit complete and accurate financial certification or 
disclosure statements to the appropriate regulatory authorities. Investigators are 
responsible for providing information on financial interests during the course of the trial and 
for 1 year after completion of the trial. 
10.1.3 Informed consent process 
Informed consent must be obtained before any trial-specific screening procedure is 
performed. 
The investigator or his/her representative will explain the nature of the trial to the trial 
subject and answer all questions regarding the trial. 
Trial subjects must be informed that their participation is voluntary. 
Trial subjects will be required to sign a statement of informed consent that meets the 
requirements of local regulations, ICH guidelines, Health Insurance Portability and 
Accountability Act (HIPAA) requirements, where applicable, and the IEC or trial site. 
The medical record must include a statement that written informed consent was obtained 
using a sponsor approved ICF before the trial subject was enrolled in the trial and the date 
the written consent was obtained. The authorized person obtaining the informed consent 
must also sign the ICF. 
Trial subjects must be re-consented to the most current version of the ICF during their 
participation in the trial. 
Informed consent will be obtained for the use of residual biosamples collected for further 
explorative investigations of the immune response in healthy adults after P/B 
immunization, e.g., using new assays that become available after completion of trial 
conduct. 
10.1.4 Data protection 
Trial subjects will be assigned a unique identifier by the investigator according to the 
sponsor specifications on unique identifier assignment. Any trial subject records or 
datasets that are transferred to the sponsor will contain the identifier only; trial subject 
names or any information which would make the trial subject identifiable will not be 
transferred. 
Trial subjects must be informed that his/her personal trial-related data will be used by the 
sponsor in accordance with local data protection laws. The level of disclosure must also be 
explained to the trial subject who will be required to give consent for their data to be used 
as described in the informed consent. 
Trial subjects who withdraw consent must be informed that the data collected up until 
consent was withdrawn will still be used by the sponsor as described in the ICF. 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 64 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
Trial subjects who withdraw consent must be informed that, unless they agree otherwise, 
any biosamples collected will be destroyed. 
Trial subjects must be informed that their medical records may be examined by sponsor 
quality assurance auditors or other authorized personnel appointed by the sponsor, by 
appropriate IEC members, and by inspectors from regulatory authorities. 
10.1.5 Committees - SRC 
For Part A, the SRC will comprise a sponsor medical representative, the Medical Monitor, 
a sponsor-independent investigator, and a site representative. 
Key roles of the SRC are as follows: 
 Before progression to the next cohort, assess the data, decide whether to approve 
initiation of the next cohort/dose level and to confirm the planned dose or define 
another dose for use. The data assessed by the SRC is defined in Section 1.1. 
 After completing its evaluation of the 48 h data for the first 6 subjects per group in 
cohort, the SRC may request a prolongation of the observation period to up to Day 7 
data for later cohorts or other similar adaptions to protect subject wellbeing. 
 Throughout the trial, assess whether to replace trial subjects permanently discontinued 
due to safety issues. 
 Throughout the trial, approval from the SRC will be required prior to resuming any 
dosing in a “stopped” cohort (see Section 6.6.1). The SRC may call for the opening of a 
lower dose level cohort. 
 SRC may make recommendations on increasing the length of the observation periods 
and additional subject wellbeing calls may be included at the discretion of the SRC. 
The SRC will act according to its own written procedures described in a charter, and will 
prepare written minutes of its meetings. 
10.1.6 Dissemination of clinical trial data 
A final clinical trial report integrating all trial results will be prepared by the sponsor. 
This trial will be registered and trial results be posted on publicly accessible trial registries 
(e.g., the EU Clinical Trial Register) in accordance with the applicable regulations. 
10.1.7 Data quality assurance 
All trial subject data relating to the trial will be recorded in a CRF unless transmitted to the 
sponsor or designee electronically (e.g., laboratory data). The investigator is responsible 
for verifying that data entries are accurate and correct by signing the CRF. 
The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF. 
The investigator must permit trial-related monitoring, audits, IEC review, and regulatory 
agency inspections and provide direct access to source data documents. 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 65 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
Monitoring details describing strategy (e.g., risk-based initiatives in operations and quality, 
such as risk management and mitigation strategies and analytical risk-based monitoring), 
methods, responsibilities and requirements, including handling of noncompliance issues 
and monitoring techniques (central, remote, or on site monitoring) are provided in the 
Monitoring Plan. 
The sponsor or designee is responsible for the data management of this trial including 
quality checking of the data. 
The sponsor assumes accountability for actions delegated to other parties (e.g., CRO). 
Trial monitors will perform ongoing source data verification to confirm that data entered 
into the CRF by authorized site personnel are accurate, complete, and verifiable from 
source documents; that the safety and rights of trial subjects are being protected; and that 
the trial is being conducted in accordance with the currently approved protocol and any 
other trial agreements, GCP, and all applicable regulatory requirements. 
Records and documents, including signed ICFs, pertaining to the conduct of this trial must 
be retained by the investigator for 30 years after trial completion unless local regulations or 
institutional policies require a longer retention period. No records may be destroyed during 
the retention period without the written approval of the sponsor. No records may be 
transferred to another location or party without written notification to the sponsor. 
10.1.8 Source documents 
Source documents provide evidence for the existence of the trial subject and substantiate 
the integrity of the data collected. Source documents are filed in the ISF. 
Data entered in the CRF that are transcribed from source documents must be consistent 
with the source documents or the discrepancies must be explained. The investigator may 
need to request previous medical records or transfer records, depending on the trial. Also, 
current medical records must be available. 
Source data are all information in original records and certified copies of original records of 
clinical findings, observations, or other activities in a clinical trial necessary for the 
reconstruction and evaluation of the trial. Source data are contained in source documents 
(original records or certified copies). 
Source documents are original documents, data, and records (e.g., hospital records, 
clinical and office charts, laboratory notes, memorandums, subject diaries or evaluation 
checklists, pharmacy dispensing records, recorded data from automated instruments, 
copies or transcriptions certified after verification as being accurate copies, microfiches, 
photographic negatives, microfilm or magnetic media, x-rays, subject files, and records 
kept at the pharmacy, at the laboratories and at medico-technical departments involved in 
the clinical trial). 
10.1.9 Trial and site start and closure 
The trial start date is the date on which the trial will be open for enrollment of trial subjects. 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 66 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
The sponsor reserves the right to close the trial site or terminate the trial at any time for 
any reason at the sole discretion of the sponsor. Trial sites will be closed upon trial 
completion. A trial site is considered closed when all required documents and trial supplies 
have been collected and a trial site closure visit has been performed. 
The investigator may initiate trial site closure at any time, provided there is reasonable 
cause and sufficient notice is given in advance of the intended termination. 
Reasons for the early closure of a trial site by the sponsor or investigator may include but 
are not limited to: 
 Failure of the investigator to comply with the protocol, the requirements of the IEC 
or local health authorities, the sponsor's procedures, or GCP guidelines. 
 Inadequate recruitment of trial subjects by the investigator. 
 Discontinuation of further trial treatment development. 
If the trial is prematurely terminated or suspended, the sponsor shall promptly inform the 
investigators, the IECs, the regulatory authorities, and any CROs used in the trial of the 
reason for termination or suspension, as specified by the applicable regulatory 
requirements. The investigator shall promptly inform the trial subject and should assure 
appropriate follow-up. 
10.1.10 
Publication policy 
The results of this trial may be published or presented at scientific meetings. If this is 
foreseen, the investigator agrees to submit all manuscripts or abstracts to the sponsor 
before submission. This will allow the sponsor to protect proprietary information and to 
provide comments. 
The sponsor will comply with the requirements for the publication of trial results. In 
accordance with standard editorial and ethical practice, the sponsor will generally support 
publication of multi-site trials only in their entirety and not as individual site data. In this 
case, a coordinating investigator will be designated by mutual agreement. 
Authorship will be determined by mutual agreement and in line with International 
Committee of Medical Journal Editors (ICMJE) authorship requirements. 
10.1.11 
Protocol preparation and approval 
This protocol has been prepared, reviewed and approved, including wet ink sign-off by the 
sponsor’s responsible person, in accordance with the sponsor’s standard operating 
procedures. Documentation of this process is filed in the Trial Master File (TMF). 
10.2 
Clinical laboratory tests 
Blood will be drawn and urine will be collected for clinical laboratory tests at the times 
given in the SoA (Section 1.3). 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 67 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
Hematology 
Hemoglobin, hematocrit, red blood cell count, white blood cell count and differential 
(neutrophils, lymphocytes, monocytes, eosinophils, basophils), platelet count. 
Clinical chemistry 
Alkaline phosphatase, creatinine, ferritin, C-reactive protein, albumin, alanine 
aminotransferase, amylase, aspartate aminotransferase, gamma glutamyl transpeptidase, 
total bilirubin, blood urea nitrogen, glucose, lipase, sodium, potassium, calcium. 
FSH: Only in women who are not of childbearing potential. 
Urinalysis 
Dipstick: glucose, bilirubin, ketone, specific gravity (1 mL ≙ 1 g), blood, pH, protein, 
urobilinogen, nitrite, and leukocytes. 
Microscopic urinalysis: If warranted by dipstick results, urine sediment will be 
microscopically examined for presence of red blood cells, white blood cells, casts, crystals, 
epithelial cells, and bacteria. 
10.3 
Adverse events: Definitions and procedures for recording, 
evaluating, follow-up, and reporting 
10.3.1 Definition of AE and TEAE 
 An AE is any untoward medical occurrence in a clinical study participant, temporally 
associated with the use of study intervention, whether or not considered related to 
the study intervention. 
NOTE: An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding that is clinically significant), symptom, or disease 
(new or exacerbated) temporally associated with the use of study intervention. 
 Events after signing ICF and before IMP administration will be handled as AEs. 
 A TEAE is defined as any AE with an onset date on or after the first administration 
of IMP (if the AE was absent before the first administration of IMP) or worsened 
after the first administration of IMP (if the AE was present before the first 
administration of IMP). AEs with an onset date more than 28 d after the last 
administration of IMP will be considered as treatment emergent only if assessed as 
related to IMP by the investigator. 
10.3.1.1 
Events meeting the AE definition 
 Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) 
or other safety assessments (e.g., ECG, radiological scans, vital signs 
measurements), including those that worsen from baseline, and which are 
considered clinically significant in the medical and scientific judgment of the 
investigator, may be considered as AEs. 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 68 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
 Reactogenicity need only be reported as an AE if doing so provides clinically 
significant information not available elsewhere (such as the solicited reactions 
listings), e.g., severe reactogenicity lasting longer than the period of solicitation of 
symptoms in the subject diary. Diagnostic AEs for local and/or systemic 
reactogenicity, e.g., “injection site reaction” or “flu-like illness”, should generally be 
preferred over AEs reporting of individual signs and symptoms. 
 New conditions or (at the discretion of the investigator) any worsening of a pre-
existing condition detected or diagnosed after Visit 0. 
 Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction. 
 Signs, symptoms, or the clinical sequelae of a suspected overdose of either trial 
treatment or a concomitant medication. Overdose per se will not be reported as an 
AE/SAE. 
10.3.1.2 
Events not meeting the AE definition 
 Medical or surgical procedure (e.g., endoscopy, appendectomy): the condition that 
leads to the procedure is the AE. 
 Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital). 
10.3.1.3 
Suspected adverse reaction 
All untoward and unintended responses to an IMP-related to any dose administered. 
 The definition also covers medication errors and uses outside what is foreseen in 
the protocol, including misuse and abuse of the IMP. 
 The definition implies a reasonable possibility of a causal relationship between the 
event and the IMP. This means that there are facts (evidence) or arguments to 
suggest a causal relationship. 
10.3.1.4 
Definition of SAE 
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met (e.g., hospitalization for signs/symptoms of the disease under trial, 
death due to progression of disease). 
An SAE is defined as any untoward medical occurrence that, at any dose: 
 Results in death 
 Is life-threatening 
The term “life-threatening” in the definition of “serious” refers to an event in which 
the trial subject was at risk of death at the time of the event. It does not refer to an 
event which hypothetically might have caused death if it were more severe. 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 69 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
 Requires trial subject hospitalization or prolongation of existing hospitalization 
− 
In general, hospitalization signifies that the trial subject has been detained 
(usually involving at least an overnight stay) at the hospital or emergency ward 
for observation and/or treatment that would not have been appropriate in the 
physician’s office or out trial subject setting. Complications that occur during 
hospitalization are AEs. If a complication prolongs hospitalization or fulfills any 
other serious criteria, the event is serious. When in doubt as to whether 
“hospitalization” occurred or was necessary, the AE should be considered 
serious. 
 Results in persistent disability/incapacity: 
− 
This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, 
influenza, and accidental trauma (e.g., sprained ankle) which may interfere with 
or prevent everyday life functions but do not constitute a substantial disruption. 
 Is a congenital anomaly or a birth defect. 
 Other situations: 
− 
Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events 
that may not be immediately life-threatening or result in death or hospitalization 
but may jeopardize the trial subject or may require medical or surgical 
treatment to prevent one of the other outcomes listed in the above definition. 
These events should usually be considered serious. 
10.3.1.5 
Suspected unexpected serious adverse reaction (SUSAR) 
All suspected adverse reactions related to an IMP (the tested drugs and comparators) that 
occur in this trial, and that are both unexpected and serious are SUSARs. SUSARs are 
subject to expedited reporting. 
10.3.1.6 
Use of the terms “severe” and “serious” 
Severity and seriousness need to be assessed independently for each AE recorded on the 
CRF. 
SAEs must be reported by the investigator to the sponsor immediately (i.e., no more than 
24 h after learning of the event; see Section 10.3.1.10 for reporting instructions). 
10.3.1.7 
Recording and follow-up of AE and/or SAE 
AE and SAE recording 
The investigator needs to assess and document any AE regardless of association with the 
use of the trial treatment during the period of observation as defined in Section 8.3.1. To 
ensure trial subject safety during the trial, safety will be monitored from Visit 0 (screening) 
until approximately 6 months after the last immunization. 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 70 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
 Data pertaining to AEs will be collected during each trial visit either based on the 
trial subject’s spontaneous description or investigator’s inquiry or discovered in the 
course of examinations done during the visit, clinical significance of any sign or 
symptom needs to be evaluated by the investigator. 
 Clinically significant findings need to be documented as AEs in the source data and 
CRF. Findings that are evaluated and documented in the source data as not 
clinically significant (e.g., an abnormal laboratory value without any clinical 
manifestation), should not be documented as AE. 
 The investigator will then record all relevant AE information in the CRF and perform 
an assessment on: 
− 
Intensity, see the section “Assessment of intensity” in Section 10.3.1.11 for 
guidance on the assessment of intensity 
− 
Seriousness 
− 
Outcome 
− 
Causal relationship of the AE to the trial treatment 
− 
Any trial treatment action and/or any other action taken 
 All assessments as well as AE term (diagnosis/description), start date and time of 
onset, end date and time need to be documented in the CRF. 
 There may be instances when copies of medical records for certain cases are 
requested by the sponsor. In this case, all trial subject identifiers, with the exception 
of the trial subject number, will be redacted on the copies of the medical records 
before submission to the sponsor. 
 To avoid colloquial expressions, the AE should be reported in standard medical 
terminology. The investigator will attempt to establish a diagnosis of the event 
based on signs, symptoms, and/or other clinical information. Whenever possible, 
the diagnosis (not the individual signs/symptoms) will be documented as the AE. If a 
definitive diagnosis is not possible, the individual signs and symptoms should be 
recorded. 
Assessment of AE and/or SAE intensity 
The assessment of AE and/or SAE intensity should be done consistently for all subjects 
treated with the same treatment and dose. In case of doubt, the Medical Monitor should be 
consulted. 
The intensity of AEs or SAEs will be graded by the investigator. For further guidance 
please refer to the US FDA Guidance for Industry “Toxicity Grading Scale for Healthy Adult 
and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials”. Where specific 
guidance for an adverse event term is not provided, the following general approach should 
be followed: 
 Grade 1 - Mild; does not interfere with the subject’s usual function. 
 Grade 2 - Moderate; interferes to some extend with the subject’s usual function. 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 71 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
 Grade 3 - Severe; interferes significantly with the subject’s usual function. 
 Grade 4 - Potentially life-threatening; life-threatening consequences, urgent 
intervention required. 
Please also refer to the intensity tables given in the guideline for intensity of clinical and 
laboratory abnormalities to be reported as AEs: 
 Guideline Section III.A for assessment of clinical abnormalities (local and systemic) 
Actions taken by the investigator 
Actions taken by the investigator as a result of an AE must be documented. 
Action(s) taken with trial treatment (IMPs) by the investigator: 
 Dose not changed (= continuation of trial treatment administration according to the 
trial protocol) 
 Dose reduced 
 Drug interrupted; i.e., interruption of IMP administration during a given visit 
 Drug withdrawn 
 Unknown (e.g., in case the trial subject is lost to follow-up) 
 Not applicable (e.g., in case treatment with trial treatment has not yet started or 
event starts after last trial treatment administration) 
Other action(s) that may be taken by the investigator include: 
 None 
 Remedial drug therapy 
 Other specific treatment(s) of AE (to be specified) 
Outcome 
The investigator has to assess the outcome of an AE (and not the trial subject’s outcome) 
at the time of documentation based on the following criteria: 
 Recovered/resolved* (= complete resolution of the AE) 
 Recovering/resolving (= AEs which are improving but not yet resolved completely, 
e.g., decrease in an intensity grade) 
 Not recovered/not resolved (= AEs which are ongoing without improving or still 
present when the trial subject deceases due to another cause) 
 Recovered/resolved with sequelae* (= trial subject recuperated but retained 
pathological conditions resulting from the AE; the sequelae should be indicated) 
 Fatal** (= death due to the AE) 
 Unknown (e.g., in case the trial subject is lost to follow-up) 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 72 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
* Generally, an AE is defined as recovered/resolved if all symptoms have ceased, no 
medication for treatment of the event is taken anymore and no other measures (e.g., 
hospitalization) are ongoing. 
If the trial subject has developed permanent or chronic symptoms or if the event requires 
long-term medication(s), the AE is defined as recovered/resolved with sequelae as soon 
as no changes of symptoms and/or medication(s) are expected anymore. 
An AE that is documented as a worsening of a medical condition already known at 
baseline, is defined as recovered as soon as the medical condition has returned to 
baseline status. 
** In case of a fatal event, the event term should not be “death” but the underlying event 
which led to death (death = outcome). If there is more than one AE in a fatal case, only the 
AE leading to death will be attributed with the outcome “fatal”. All other AEs ongoing at the 
time of death will be attributed with the outcome “not recovered/not resolved”. A copy of an 
autopsy report should be submitted if available. 
Assessment of causality 
The investigator is obligated to assess the relationship between trial treatment/trial 
procedure and each occurrence of each AE/SAE. 
The investigator will use clinical judgment to determine the relationship. 
Alternative causes, such as underlying disease(s), concomitant therapy, and other risk 
factors, as well as the temporal relationship of the event to trial treatment administration 
will be considered and investigated. 
It is sufficient to document the causality in the source data and CRF as: 
 Related (= there is a reasonable possibility of a causal relationship) or 
 Not related (= there is no reasonable possibility of a causal relationship) 
Relationship to trial treatment 
 The relationship or association of an AE or SAE to a trial treatment will be made by 
the investigator after having evaluated all accessible data and, if necessary, he/she 
will re-evaluate the case as new information becomes available. 
 Events caused by the procedure of trial treatment administration should be 
differentiated from events caused by the trial treatment itself. Only events suspected 
to be caused by the IMPs itself should be documented as suspected. 
Relationship to trial procedures 
 In this trial, it cannot be excluded that during the course of the trial some procedures 
give rise to AEs which are related to the trial procedure and not to the trial 
treatment. Procedure-related AEs can occur on the site of injection of the trial 
treatment e.g., redness, swelling, hematoma, or itching or during or after trial-
specific procedure, e.g., discomfort after blood drawing. 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 73 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
 There may be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to the sponsor. However, it is very 
important that the investigator always makes an assessment of causality for every 
event before the initial transmission of the SAE data to the sponsor. 
 The investigator may change his/her opinion of causality in light of follow-up 
information and send an SAE follow-up report with the updated causality 
assessment. 
 The causality assessment is one of the criteria used when determining regulatory 
reporting requirements. 
10.3.1.8 
SAE exemptions 
In general, SAEs are defined according to ICH Topic E2A (CPMP/ICH/377/95), 
EU Directive 2001/20/EC, and ENTR/CT-3 (see Section 10.3.1.4). 
In the present trial, some events are excluded from the SAE definition. The following 
events do not need to be reported as SAEs: 
 AEs and SAEs occurring after trial subject discharge from the trial must only be 
reported by the investigator to the sponsor if a relationship to trial treatment or trial 
procedure is suspected. 
 Planned hospitalizations required by the protocol (e.g., for trial treatment 
administration) will not be considered as reportable SAE. 
10.3.1.9 
Documentation of particular situations 
AEs that are secondary to other events: 
In general, AEs that are secondary to other events (e.g., cascade events or clinical 
sequelae) should be identified by their primary cause, with the exception of severe or 
serious secondary events. A medically significant secondary AE that is separated in time 
from the initiating event should be documented as an independent AE in source data and 
CRF. For example: 
 If vomiting results in mild dehydration with no additional treatment in a healthy adult, 
only vomiting should be documented as AE. 
 If vomiting results in severe dehydration, both events should be documented as AEs 
separately. 
Abnormal laboratory results and vital signs values: 
Not every laboratory or vital signs abnormality needs to be documented as AE. For 
clinically significant laboratory/vital signs abnormalities the following definitions and 
documentation rules apply: 
 If a laboratory/vital signs abnormality is a sign of a disease or syndrome, the 
laboratory/vital signs abnormality is clinically significant and only the diagnosis of 
the causing disease or syndrome needs to be documented as AE. 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 74 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
 If a laboratory/vital signs abnormality results in specific symptoms but no diagnosis 
of a disease or syndrome can be made, the laboratory/vital signs abnormality is 
clinically significant and only the symptoms need to be documented as AEs. 
 If a laboratory/vital signs abnormality is not a sign of a disease or syndrome and 
does not result in specific symptoms but leads to a change in trial treatment or in a 
medical intervention, the laboratory/vital signs abnormality is clinically significant 
and must be documented as AE. 
 If a laboratory/vital signs abnormality is not considered clinically significant by the 
investigator, then an AE does not need to be documented. 
AEs associated with an overdose or error in drug administration: 
An overdose is the accidental or intentional use of a drug in an amount (per administration 
or cumulatively) higher than the dose being studied (for the trial treatment) or higher than 
the maximum recommended dose according to the authorized product information (for 
approved concomitant medications). An overdose or incorrect administration of a drug is 
not itself an AE, but it may result in an AE. 
All AEs associated with an overdose or incorrect administration should be documented as 
AE in source data and CRF and reported as SAE if applicable. 
AEs of proven COVID-19 disease: 
Any case of proven COVID-19 disease occurring until the last planned FU Visit should be 
reported as an SAE/AE. AEs which are rated as “moderate” or “severe” (according to the 
criteria provided in Section 10.3.1.7) will need to be reported as an SAE. If none of the 
other SAE definitions are deemed suitable, then the SAE criterion of being a “medically 
important event” should be applied (according to the definitions provided in 
Section 10.3.1.4). An SAE form should be completed, including follow-up information, as 
detailed in Section 10.3.1.10 such that an SAE report and narrative can be prepared and 
distributed. All mild cases of proven COVID-19 cases which do not correspond to 
seriousness criteria will need to be reported as an AE in the CRF. 
10.3.1.10 
Reporting of SAEs 
All SAEs or DLTs (even if non-serious) which occur in a trial subject during the observation 
period, whether considered to be associated with trial medication or not, must be reported 
by the investigator to the sponsor within 24 h following knowledge of the event. 
All SAEs occurring after the end of the period of observation only have to be reported to 
the sponsor if the investigator suspects a relationship to trial medication or the trial 
procedure. 
SAE reporting to sponsor using a paper form (SAE report) 
For the period of observation, see Section 8.3.1. 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 75 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
For any SAE or DLT (even if non-serious), the investigator needs to complete the paper 
Serious Adverse Event Form which must be sent to the sponsor via one of the following 
reporting methods: 
 Safety Report Fax No.:  
 
+49 (0) 231 
 
 Safety Report Email Address:  
 
Information for final description and evaluation of a case report may not be available within 
the required time frames for reporting. Nevertheless, for regulatory purposes, initial reports 
should be submitted if the following minimal information is available: 
 An identifiable trial subject (trial subject number) 
 A suspected medicinal product 
 An identifiable reporting source (investigator/trial site identification) 
 An event or outcome that can be identified as serious 
SAE follow-up information should be sent to the sponsor (indicating that this is a “follow-
up” report using the SAE Form or the Additional Information and Follow-Up Form) without 
delay as described above and accompanied by appropriate anonymous supporting 
documentation (e.g., discharge letters, medical reports or death certificates), until a final 
outcome and date are available. All confidential information (name, address, full day of 
birth) needs to be blackened before sending. In addition to a medical record, the 
investigator should complete an Additional Information and Follow-Up Form, which 
contains the SAE term and trial subject number. 
A copy of the submitted SAE report must be retained on file by the investigator. If explicitly 
required according to national legislation, the investigator must submit copies of the SAEs 
to the IEC or authority and retain documentation of these submissions in the ISF. 
In case an investigator or any other trial team member has questions on safety reporting 
the sponsor may be contacted via: Email: pharmacovigilance@biontech.de. 
For medical questions, the sponsor’s Medical Monitor for this trial should be contacted. 
10.3.1.11 
Assessments of intensity for solicited local and systemic reactions 
and laboratory abnormalities 
The grading of solicited local and systemic reactions, recorded in the subject diaries, will 
be according to the following guidance, in line with Guideline Section III.A for assessment 
of clinical abnormalities (local and systemic). 
Local reactions 
Redness and swelling / induration will be measured and recorded in centimeters and then 
categorized during analysis as absent, mild, moderate, severe or potentially life-
threatening, based on the grading scale in Table 4. Likewise, pain (perceived) and 
tenderness (elicited) at the injection site will be assessed by the trial subject as absent, 
mild, moderate, severe, or potentially life-threatening, according the grading scale in 
Table 4. 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 79 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
Note: Documentation can come from the site personnel review of the trial subject’s 
medical records, medical examination, or medical history interview. 
Post-menopausal female 
A post-menopausal state is defined as no menses for 12 months without an alternative 
medical cause. 
A high FSH level in the post-menopausal range may be used to confirm a post-
menopausal state in women not using hormonal contraception or hormonal replacement 
therapy (HRT). However, in the absence of 12 months of amenorrhea, confirmation with 
more than one FSH measurement is required. 
Females on HRT and whose menopausal status is in doubt will be required to use one of 
the non-estrogen hormonal highly effective contraception methods if they wish to continue 
their HRT during the trial. Otherwise, they must discontinue HRT to allow confirmation of 
post-menopausal status before trial enrollment. 
10.4.2 Contraception guidance 
WOCBP must confirm that they practiced at least one highly effective form of 
contraception for the 14 d prior to Visit 0. 
WOCBP must practice a highly effective form of contraception during the trial, starting after 
Visit 0 and continuously until 60 d after receiving the last immunization. WOCBP must 
agree to require their male partners to use condoms during sexual contact (unless male 
partners are sterilized or infertile). 
Men who are sexually active with a WOCBP and have not had a vasectomy must agree to 
practice a highly effective form of contraception with their female partner of childbearing 
potential during the trial, starting after Visit 0 and continuously until 60 d after receiving the 
last immunization. 
Subjects with bilateral tubal occlusion, previous successful vasectomy or those who are 
truly abstinent or exclusively homosexual are deemed as being “not of reproductive 
potential”. 
The investigator or delegate should advise the subject how to achieve highly effective 
contraception. The following birth control methods may be considered as highly effective: 
 Intrauterine device. a 
 Intrauterine hormone-releasing system. a 
 Combined estrogen and progestogen-based contraception: established use of oral, 
intravaginal, or transdermal hormonal methods of contraception. 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 80 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
 Progesterone-based contraception: established use of oral, injected, or implanted a 
hormonal methods of contraception. 
a) Contraception methods that in the context of this guidance are considered to have low user dependency. 
10.4.3 Collection of pregnancy information 
Pregnancy information will only be collected after obtaining written informed consent from 
the pregnant female trial subject (or if a male trial subjects’ partner becomes pregnant, 
written informed consent from both). 
Pregnancy information will be collected for pregnancies that occurred after the start of trial 
intervention and until 60 d after the last administration of IMP for pregnant trial subjects (or 
until 60 d after the last administration of IMP to the male trial subject for pregnant female 
partners). 
The initial and follow-up information must be documented on the paper-based Pregnancy 
Reporting Form and submitted to the sponsor within 24 h of learning of a trial subject’s 
pregnancy/partner’s pregnancy. The completed form needs to be sent to the Safety Report 
Fax number or Email given in Section 10.3.1.10. Completed pregnancy forms must be 
signed by an investigator before faxing/mailing them to the sponsor. Blank reporting forms 
are provided to the investigator during the site initiation visit and are filed in the ISF. 
The investigator will collect follow-up information on the trial subject/trial subject’s partner 
and the neonate and the information will be forwarded to the sponsor. Pregnancy follow-up 
should describe the outcome of the pregnancy, including any voluntary or spontaneous 
termination, details of the birth, the presence or absence of any congenital abnormalities, 
birth defects, maternal or newborn complications and their presumed relation to the IMP. 
Generally, the follow-up will be of a duration determined in consultation with the 
pediatrician. 
While pregnancy itself is not considered to be an AE or SAE, any pregnancy complication 
or elective termination of a pregnancy will be reported as an AE or SAE. 
A spontaneous abortion is always considered to be an SAE and will be reported as such. 
Any post-trial pregnancy related SAE considered reasonably related to the trial 
intervention by the investigator will be reported to the sponsor. While the investigator is not 
obligated to actively seek this information in former trial subjects, he or she may learn of 
an SAE through spontaneous reporting. 
10.4.4 Sperm donation 
Men must refrain from sperm donation, starting after Visit 0 and continuously until 60 d 
after receiving the last immunization. 
10.5 
Genetics 
Not applicable. 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 81 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
10.6 
Liver safety: Suggested actions and follow-up assessments 
Not applicable. 
10.7 
Investigators and trial administrative structure 
10.7.1 Investigators and trial site personnel 
There must be an investigator at each trial site. 
If the trial is conducted by a team of individuals at the trial site, the investigator leading and 
responsible for the team is called the principal investigator. 
All persons assigned responsibility as principal investigator must sign a declaration of their 
responsibilities and their agreement to this protocol before any trial-related procedure is 
performed. 
Curriculum vitae and/or other relevant documents confirming the current qualification of 
the investigators must be provided to the sponsor. This should include any previous 
training in the principles of GCP, experience obtained from work with clinical trials, and 
experience with trial subject care. 
Documentation of all involved investigators must be maintained according to GCP and 
applicable regulatory requirements. 
10.7.2 Trial site personnel assigned trial-related duties 
The principal investigator or deputy may define appropriately qualified personnel at a trial 
site to perform significant trial-related procedures and/or to make trial-related decisions 
under his/her supervision. In this case, the principal investigator must maintain a signed 
list of the persons to whom they delegate significant trial-related duties/responsibilities; the 
delegated trial-related duties/responsibilities must be specified in the list. 
When personnel or responsibility changes are made, the principal investigator or deputy 
must ensure that the relevant documentation is updated before any trial-related activities 
are performed. 
Documentation of all involved trial site personnel performing significant trial-related 
procedures and/or making trial-related decisions must be maintained according to GCP 
and applicable regulatory requirements. 
10.7.3 Contract research organizations 
Documentation of all involved CROs must be maintained according to GCP and applicable 
regulatory requirements. This includes documentation of any delegation of responsibilities 
to CROs. 
10.7.4 The sponsor and sponsor’s personnel 
The trial sponsor listed on the title page accepts the responsibilities of the sponsor 
according to GCP and applicable regulatory requirements. 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 100 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
 
Due to the IM route the risk of severe systemic reactions is considered low. 
 
An IM vaccine based on … 
 
As with other vaccines, a… 
 
The available non-clinical data of BNT162b suggest a favorable safety profile with 
events that are short-lived, mild and mostly related to the mode-of-action and the RNA-
intrinsic stimulation of innate immune sensors. 
 
Section 4.3 (Justification for dose) 
Based on the available immunogenicity and CMI response data after dosing with BNT162b1 and 
BNT162b2 in younger and elderly adults in the BNT162-01 and BNT162-02 trials (see the BNT162 
IB), the BNT162b3 doses planned in this trial in older adults are also expected to show measurable 
responses. The sponsor will continue to evaluate these emerging data from these ongoing studies to 
inform progression to discretionary dose levels. These vaccines elicited measurable but lower 
responses in elderly adults than in younger adults, therefore, this trial includes the option to 
investigate BNT162b3 doses above the 30 µg BNT162b1 / BNT162b2 doses already tested in elderly 
adults, to support any future Phase III program planned to support marketing approval. 
Altogether, the doses planned in older adults in this trial are considered adequate to support the trial 
objectives and to pose an acceptable risk to trial subjects. 
Altogether, the doses planned in older adults in this trial are considered adequate to support the trial 
objectives and to pose an acceptable risk to trial subjects. 
 
Data update 
and deletion 
of a 
duplication 
Section 4.4 (End of Treatment (EoT) and end of trial definition) 
A trial subject is considered to have completed the trial if they have completed all planned visits as 
listed in the SoA (see Section 1.3). The EoT is defined as the date the last subject completed the EoT 
Visit. 
A trial subject is considered to have completed the trial if they have completed all planned visits as 
listed in the SoA, including all follow-up visits (see Section 1.3). The End of Treatment is defined as 
the date the last subject completed the EoT Visit (Visit 7). When entering the follow-up phase, i.e., 
after completing the EoT Visit, subjects are allowed to participate in other clinical trials not 
investigating COVID-19 vaccines or treatments. 
The end of trial is defined as the date when the last subject completed Visit 10 (Last Subject Last 
Visit). 
 
Data update 
Section 5.2.1 (Exclusion criteria Part A) 
28. Are soldiers, subjects persons in detention, CRO or sponsor staff or their family members. 
29. For older subjects: hHave a condition known to put them at high risk for severe COVID-19, 
including those with any of the following risk factors: 
o 
Cancer 
o 
Chronic kidney disease 
o 
COPD (chronic obstructive pulmonary disease) 
o 
Immunocompromised state (weakened immune system) from solid organ transplant 
o 
Obesity (BMI of 30 or higher) 
o 
Serious heart conditions, such as heart failure, coronary artery disease, or cardiomyopathies 
o 
Sickle cell disease 
o 
Type 2 diabetes mellitus 
o 
Hypertension 
o 
Diabetes mellitus 
o 
Chronic pulmonary disease 
o 
Asthma 
o 
Chronic liver disease 
o 
Known Stage 3 or worse chronic kidney disease (glomerular filtration rate <60 mL/min/1.73 
m2) 
o 
Anticipating the need for immunosuppressive treatment within the next 6 months 
o 
Resident in a long term facility 
Sponsor 
decision 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 101 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
o 
Current vaping or smoking (occasional smoking is acceptable) 
o 
History of chronic smoking within the prior year 
 
Section 6.6 (Dose modification) 
The decision to make dose adaptions or to initiate a cohort, will be made by the SRC based on 
emerging data from this and other ongoing studies with related vaccine constructs. Dose escalation 
decisions will be validated by the SRC (for details, see Section 10.1.5); any plan to alter exceed the 
planned dose escalations will only be implemented after relevant approval of a substantial protocol 
amendment. Dose de-escalation and escalation rules have been defined in this protocol (see Section 
6.6.2). 
 
Clarification 
Section 6.6.1 (Dose limiting toxicity) 
 Two trial subjects (at any dose level) with the same or similar severe (Grade 3 or higher) AE or 
reactogenicity (including clinically significant laboratory abnormalities) within 7 days of 
vaccination, considered related, or for which there is no alternative, plausible, attributable cause 
(for severity grading of AEs see Section 10.3.1.7). 
 
Clarification 
Section 6.6.2 (Dose modification guidance/rules) 
Part A 
 Any proposal to alter a planned escalation dose, or test a lower dose required for safety de-
escalation must be approved by the SRC. 
 Any proposal to alter the planned escalation dose, or to test an additional de escalation dose, 
must be approved by the SRC. 
 
Dose escalation: 
 Dose … 
 Any proposal to alter the planned escalation doses must be approved by the SRC 
 Any proposed alteration to the planned escalation dose level to a smaller or larger escalation 
increment than that shown in Table 1 must be approved by the SRC. 
 Any proposal to exceed the planned maximum dose for the trial will only be implemented after 
relevant approval of a substantial amendment. 
 
Clarification 
Section 8.2.8 (Subject diaries) 
Trial subjects will be given subject diaries at Visit 1 and be asked to record any AEs between visits, 
solicited local reactions at the injection site (pain, tenderness, erythema/redness, induration/swelling), 
and solicited systemic reactions AEs (nausea, vomiting, diarrhea, headache, fatigue, myalgia, 
arthralgia, chills, loss of appetite, malaise, and fever [i.e., ≥38°C]). 
 
Clarification 
Section 8.2.9 (Assessment of local reactions) 
Local reactions after IM immunization will be assessed by the investigator at the times given in the 
SoA (Section 1.3). This information will be used to validate the solicited assessment of local reactions 
in the subject diary and potentially support AE reporting. 
Local reactions (via daily solicited reports in the subject diaries and as assessed on visit days by the 
investigator) will be graded based on the guidance using the criteria given in the US FDA Guidance 
for Industry “Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in 
Preventive Vaccine Clinical Trials” for “local reaction to injectable products” (see the section 
“Assessment of intensity” in Section 10.3.1.11). The reporting of local reactions will be based on the 
subject’s assessment only. 
 
Clarification 
Section 8.2.13 (Assessment of systemic reactions) 
Systemic reactions after IM immunization will be assessed via daily solicited reports in the subject 
diaries and at the times given in the SoA (Section 1.3). 
Systemic reactions will be graded using criteria based on the guidance the criteria given in US FDA 
Guidance for Industry “Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in 
Sponsor 
decision and 
clarification 
of an in-
consistency 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 102 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
Preventive Vaccine Clinical Trials” for “systemic reaction grading scale” (see the section “Assessment 
of intensity” in Section 10.3.1.11). 
 
Section 8.7 (Genetics) 
A blood sample (blood and / or isolated peripheral blood mononuclear cells [PBMCs]) …… 
Further, an additional blood sample may also be used for profiling (e.g., by use of next-generation 
sequencing) of TCRs in peripheral blood after vaccination. 
Any remaining material from the blood sample after completion of the immunogenicity assessments 
may be used for the analyses as described here. 
 
To enable 
more genetic 
analyses 
Section 8.8 (Biomarkers) 
Blood draws for explorative biomarker/immunogenicity research purposes will be taken at the times 
listed in the SoA (Section 1.3). 
Instructions on the sample collection, handling, and shipping will be provided in a Laboratory Manual. 
The methodology used for these assessments will be documented in the Biomarker Manual. Up to 5 
additional blood draws (with up to 200 mL in total) will be taken over the complete trial for explorative 
biomarker/immunogenicity research purposes. 
 
Sponsor 
decision 
(alignment 
with 
BNT162-01) 
Section 8.10 (Blood collection) 
Up to approximately 592 602 mL blood will be drawn per subject over the complete trial, i.e., over 
approximately 13 16 months. 
 
Sponsor 
decision to 
add an 
additional 
blood draw 
  
Section 9.4.2 (Primary endpoints) 
Moreover, the number and percentage of subjects with any AE will be summarized by worst grade by 
PT nested within SOC. 
Local reactions and systemic reactions will be graded using criteria based on the guidance the criteria 
given in US FDA Guidance for Industry “Toxicity Grading Scale for Healthy Adult and Adolescent 
Volunteers Enrolled in Preventive Vaccine Clinical Trials” (see Section 10.3.1.11). 
For each immunization, the number and percentage of subjects reporting at least one local reaction or 
systemic reaction (i.e., solicited data collected using subject diaries) will be summarized for each of 
the following types using the Safety Set: 
 Any local reactions or systemic reactions 
 Grade ≥3 local reactions or systemic reactions 
The analysis of local and systemic reactions will be repeated with a reduced set of terms (called the 
“alignment analysis set”), to enable like-for-like evaluations when these data are informally set 
alongside the data from other trials in the clinical development program for BNT162 vaccines. 
 
Clarification  
Section 9.4.5 (Other safety analyses) - Clinical laboratory parameters 
Abnormal laboratory results will be graded using criteria based on the guidance the criteria given in 
US FDA Guidance for Industry “Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers 
Enrolled in Preventive Vaccine Clinical Trials” (see Section 10.3.1.11). 
 
Clarification 
of an in-
consistency 
Section 10.9 (Other standard abbreviations and definitions) 
EoT 
End of Trial Treatment 
 
This update 
Section 10.10 (Protocol amendments and updates) 
10.10 Protocol amendments and updates 
10.10.1 Update to protocol version 2.0 
Update rationale 
This update describes changes made in response to internal feedback before submission of version 
2.0 to the German PEI. 
Sponsor 
decision to 
differentiate 
between 
sponsor 
approved 
versions and 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 109 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
10.10.7 
Protocol amendment no. 02 (protocol version 8.0) 
Update rationale 
This update implements: a change in sponsor name; the addition of two additional dosing 
cohorts in older adults; measures to avoid under reporting of mild COVID-19 related 
events revealed within the trial; terminology alignment with other ongoing trials; correction 
so some errors. 
The rational for the addition of two older adult cohorts is that based on the available 
immunogenicity and CMI response data after dosing with BNT162b1 and BNT162b2 in 
younger and elderly adults in the BNT162-01 and BNT162-02 trials (see the BNT162 IB) 
elicited measurable but lower responses in elderly adults than in younger adults. 
Therefore, the additional older adult cohorts will be used to investigate BNT162b3 doses 
above the already tested 20 µg BNT162b3 dose, to support any future Phase III program 
planned to support marketing approval. 
A detailed description of the changes is given below. 
This amendment was issued after the first trial subjects have been enrolled into the trial. 
This change has no impact on the planned trial objectives or subject safety. 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 130 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
10.11 
Data collection and management 
The trial documentation must be adequate for the reconstruction of the trial. 
10.11.1 
Case report forms 
CRFs will be completed through use of an electronic data capture (EDC) system. Trial site 
personnel will receive training and have access to a manual for appropriate CRF 
completion. The CRFs will be submitted electronically to the sponsor via the system and 
should be handled in accordance with instructions from the sponsor. 
All CRFs should be completed by designated, trained trial site personnel. CRFs should be 
reviewed, verified, and then electronically signed and dated by the investigator or a 
designee. 
At the end of the trial, the investigator will receive trial subject data for his/her trial site in a 
readable format that must be kept with the trial records. Acknowledgment of receipt of the 
trial subject data will be required. 
10.11.2 
Trial subject reported outcomes 
Not applicable. 
10.11.3 
Data management 
The CRO (see the title page) will be responsible for data management of this trial, 
including quality checking of the data. 
Data entered manually will be submitted to the sponsor through use of an EDC system, 
data extracts, and reports. Trial sites will be responsible for data entry into the EDC 
system. In the event of discrepant data, the data management service provider will request 
data clarification from the trial sites, which the trial sites will resolve electronically in the 
EDC system. 
The data management service provider will produce a Trial Data Validation Specification 
document that describes the quality checking to be performed on the data. CRFs and 
correction documentation will be maintained in the EDC system's audit trail. 
Central laboratory data will be sent directly to the data management service provider. 
System backups for data stored by the sponsor and records retention for the trial data will 
be in accordance with regulatory requirements. 
10.11.4 
Investigator’s Site File and the Trial Master File 
The principal investigator or deputy is responsible for the filing of all essential documents 
in an ISF. The sponsor is responsible for the timely filing of all essential documents in the 
TMF. As applicable, these files must be available at monitoring visits and during audits or 
regulatory inspections. 
After trial completion, the principal investigator or deputy must ensure that all source data 
and documentation related to the trial is recorded, handled, and stored in a way that allows 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 131 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
its accurate reporting, interpretation, and verification. The principal investigator or deputy 
must take measures to prevent accidental or premature destruction of these documents. 
The principal investigator or deputy must keep the ISF, the source data/documentation 
arising from the trial according to the prescribed record retention period in the country 
and/or according to the hospital policy, but at least until informed by the sponsor that the 
trial-related records are no longer required. 
10.12 
Other data 
10.12.1 
Demographic data 
At screening, the following demographic data will be recorded for all trial subjects: 
 Age (in years/months) 
 Gender (male/female) 
 Ethnic group 
10.12.2 
Medical history 
Medical history information will be recorded for at the times given in the SoA (Section 1.3). 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 132 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
11 
REFERENCES 
BNT162 Investigator’s brochure, current edition. 
EMA Guidance 2017. Strategies to Identify and Mitigate Risks for First-in-Human and 
Early Clinical Trials with Investigational Medicinal Products. European Medicines Agency 
(EMA) Science Medicines Health. 
FDA Guidance 2007. US FDA Guidance for Industry. Toxicity Grading Scale for Healthy 
Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. 
Feldman RA, Fuhr R, Smolenov I, et al. mRNA vaccines against H10N8 and H7N9 
influenza viruses of pandemic potential are immunogenic and well tolerated in healthy 
adults in phase 1 randomized clinical trials. Vaccine. 2019; 37(25): 3326-34. 
Moyo N, Vogel AB, Buus S, et al. Efficient Induction of T Cells against Conserved HIV-1 
Regions by Mosaic Vaccines Delivered as Self-Amplifying mRNA. Mol Ther Methods Clin 
Dev. 2018; 12: 32-46. 
NCT04523571. BNT162-03. Safety and immunogenicity of SARS-CoV-2 mRNA vaccine 
(BNT162b1) in Chinese healthy subjects: A Phase I, randomized, placebo-controlled, 
observer-blind study. Ongoing BioNTech clinical trial. 
NCT04368728. BNT162-02/C4591001. Study to describe the safety, tolerability, 
immunogenicity, and efficacy of RNA vaccine candidates against COVID-19 in healthy 
individuals. Study Intervention Number: PF-07302048. Ongoing BioNTech clinical trial. 
NCT04380701. BNT162-01. A multi-site, Phase I/II, 2-part, dose escalation trial 
investigating the safety and immunogenicity of four prophylactic SARS-CoV-2 RNA 
vaccines against COVID-19 using different dosing regimens in healthy adults. Ongoing 
BioNTech clinical trial. 
Pardi N, Hogan MJ, Pelc RS, et al. Zika virus protection by a single low-dose nucleoside-
modified mRNA vaccination. Nature. 2017; 543 (7644): 248-51. 
Rauch S, Jasny E, Schmidt KE, Petsch B. New Vaccine Technologies to Combat 
Outbreak Situations. Front Immunol. 2018; 9: 1963. 
Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics-developing a new class of drugs. 
Nat Rev Drug Discov. 2014; 13 (10): 759-80. 
US Center for Disease control and Prevention (CDC). Coronavirus Disease 2019 
(COVID-19) guidance webpage. Accessed July 14th, 2020: 
https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-
conditions.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F20
19-ncov%2Fneed-extra-precautions%2Fgroups-at-higher-risk.html 
Vogel AB, Lambert L, Kinnear E, et al. Self-Amplifying RNA Vaccines Give Equivalent 
Protection against Influenza to mRNA Vaccines but at Much Lower Doses. Mol Ther. 
2018; 26 (2): 446-55. 
Weissman D and Karikó K. mRNA: Fulfilling the Promise of Gene Therapy. 2015; Mol 
Ther. 2015; 23(9): 1416-17. 

BioNTech SE 
Confidential 
Clinical Trial Protocol Including  
Amendments Nos. 01 to 04 
BNT162-04 
Page 133 of 133 
Version: 10.0 
Date: 12 MAY 2021 
 
 
WHO “Protection measures for persons who are in or have recently visited (past 14 days) 
areas where COVID-19 is spreading”. Accessed at: 
https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public 
WHO Situation Report Nr. 160, June 30th, 2020. Accessed at: 
https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/